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A B S T R A C T
Background
Typhoid fever and paratyphoid fever continue to be important causes of illness and death, particularly among children and adolescents
in south-central and southeast Asia. Two typhoid vaccines are widely available, Ty21a (oral) and Vi polysaccharide (parenteral). Newer
typhoid conjugate vaccines are at varying stages of development and use. The World Health Organization has recently recommended
a Vi tetanus toxoid (Vi-TT) conjugate vaccine, Typbar-TCV, as the preferred vaccine for all ages.
Objectives
To assess the effects of vaccines for preventing typhoid fever.
Search methods
In February 2018, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase,
LILACS, and mRCT. We also searched the reference lists of all included trials.
Selection criteria
Randomized and quasi-randomized controlled trials (RCTs) comparing typhoid fever vaccines with other typhoid fever vaccines or
with an inactive agent (placebo or vaccine for a different disease) in adults and children. Human challenge studies were not eligible.
Data collection and analysis
Two review authors independently applied inclusion criteria and extracted data, and assessed the certainty of the evidence using the
GRADE approach. We computed vaccine efficacy per year of follow-up and cumulative three-year efficacy, stratifying for vaccine type
and dose. The outcome addressed was typhoid fever, defined as isolation of Salmonella enterica serovar Typhi in blood. We calculated
risk ratios (RRs) and efficacy (1 − RR as a percentage) with 95% confidence intervals (CIs).
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Main results
In total, 18 RCTs contributed to the quantitative analysis in this review: 13 evaluated efficacy (Ty21a: 5 trials; Vi polysaccharide: 6
trials; Vi-rEPA: 1 trial; Vi-TT: 1 trial), and 9 reported on adverse events. All trials but one took place in typhoid-endemic countries.
There was no information on vaccination in adults aged over 55 years of age, pregnant women, or travellers. Only one trial included
data on children under two years of age.
Ty21a vaccine (oral vaccine, three doses)
A three-dose schedule of Ty21a vaccine probably prevents around half of typhoid cases during the first three years after vaccination
(cumulative efficacy 2.5 to 3 years: 50%, 95% CI 35% to 61%, 4 trials, 235,239 participants, moderate-certainty evidence). These
data include patients aged 3 to 44 years.
Compared with placebo, this vaccine probably does not cause more vomiting, diarrhoea, nausea or abdominal pain (2 trials, 2066
participants; moderate-certainty evidence), headache, or rash (1 trial, 1190 participants; moderate-certainty evidence); however, fever
(2 trials, 2066 participants; moderate-certainty evidence) is probably more common following vaccination.
Vi polysaccharide vaccine (injection, one dose)
A single dose of Vi polysaccharide vaccine prevents around two-thirds of typhoid cases in the first year after vaccination (year 1: 69%,
95% CI 63% to 74%; 3 trials, 99,979 participants; high-certainty evidence). In year 2, trial results were more variable, with the vaccine
probably preventing between 45% and 69% of typhoid cases (year 2: 59%, 95% CI 45% to 69%; 4 trials, 194,969 participants;
moderate-certainty evidence). These data included participants aged 2 to 55 years of age.The three-year cumulative efficacy of the
vaccine may be around 55% (95% CI 30% to 70%; 11,384 participants, 1 trial; low-certainty evidence). These data came from a single
trial conducted in South Africa in the 1980s in participants aged 5 to 15 years.
Compared with placebo, this vaccine probably did not increase the incidence of fever (3 trials, 132,261 participants; moderate-certainty
evidence) or erythema (3 trials, 132,261 participants; low-certainty evidence); however, swelling (3 trials, 1767 participants; moderate-
certainty evidence) and pain at the injection site (1 trial, 667 participants; moderate-certainty evidence) were more common in the
vaccine group.
Vi-rEPA vaccine (two doses)
Administration of two doses of the Vi-rEPA vaccine probably prevents between 50% and 96% of typhoid cases during the first two
years after vaccination (year 1: 94%, 95% CI 75% to 99%; year 2: 87%, 95% CI 56% to 96%, 1 trial, 12,008 participants; moderate-
certainty evidence). These data came from a single trial with children two to five years of age conducted in Vietnam.
Compared with placebo, both the first and the second dose of this vaccine increased the risk of fever (1 trial, 12,008 and 11,091
participants, low-certainty evidence) and the second dose increase the incidence of swelling at the injection site (one trial, 11,091
participants, moderate-certainty evidence).
Vi-TT vaccine (two doses)
We are uncertain of the efficacy of administration of two doses of Vi-TT (PedaTyph) in typhoid cases in children during the first year
after vaccination (year 1: 94%, 95% CI−1% to 100%, 1 trial, 1625 participants; very low-certainty evidence). These data come from
a single cluster-randomized trial in children aged six months to 12 years and conducted in India. For single dose Vi-TT (Typbar-TCV),
we found no efficacy trials evaluating the vaccine with natural exposure.
There were no reported serious adverse effects in RCTs of any of the vaccines studied.
Authors’ conclusions
The licensed Ty21a and Vi polysaccharide vaccines are efficacious in adults and children older than two years in endemic countries.
The Vi-rEPA vaccine is just as efficacious, although data is only available for children. The new Vi-TT vaccine (PedaTyph) requires
further evaluation to determine if it provides protection against typhoid fever. At the time of writing, there were only efficacy data
from a human challenge setting in adults on the Vi-TT vaccine (Tybar), which clearly justify the ongoing field trials to evaluate vaccine
efficacy.
P L A I N L A N G U A G E S U M M A R Y
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Vaccines for preventing typhoid fever
What was studied in this review?
Typhoid fever is a bacterial infection found mainly among children and adolescents in southern and eastern Asia, Africa, Latin America,
and the Caribbean. Typhoid fever spreads through contaminated food, drink, or water. It is usually characterized initially by fever,
headache, and abdominal symptoms, although other non-specific symptoms may be present. The infection also sometimes causes
confusion or psychosis. In late stages of the infection, intestinal perforation or massive intestinal haemorrhage may occur. Treatment
normally consists of antibiotics, but problems with drug-resistant bacteria strains have been reported. Improved sanitation and food
hygiene are important control measures. However, these are associated with socioeconomic progress that has been slow in most affected
areas. Therefore vaccination is an effective way to try to prevent this disease.
What are the main results?
We found 18 relevant trials that evaluated four vaccines: 9 reported on vaccine effectiveness only, 4 reported on effectiveness and side
effects, and 5 reported on side effects only (we could not analyse one additional trial on adverse events that met the inclusion criteria as
it did not provide enough information). The two main vaccines currently licensed for use, Ty21a and Vi polysaccharide, were effective
in reducing typhoid fever in adults and children over two years in endemic countries; adverse events such as nausea, vomiting, and
fever were rare. Other vaccines, such as new, modified, conjugated Vi vaccines called Vi-rEPA and Vi-TT, are in development. These
could be given to infants, which would be helpful as they are probably at higher risk for infection, although further evidence for these
vaccines is still needed.
How up-to-date is this review?
We searched for studies published up to 14 February 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ty21a vaccination (three doses) versus placebo for typhoid fever
Patient or population: adults and children aged 5 years of age and older
Settings: any
Intervention: oral Ty21a (3 doses) - liquid, enteric capsule, or gelat in capsule
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ty21a (3 doses)
Cases of typhoid fever,
Year 1
Medium- risk population RR 0.55 (0.35 to 0.86) 76,296
(3 studies)
⊕⊕⊕©
Moderatea,b,c,d
Due to imprecision
Cases of typhoid fever
are probably reduced
with vaccinat ion
4 per 10,000 2 per 10,000
(1 to 3)
High- risk population
59 per 10,000 32 per 10,000
(21 to 51)
Cases of typhoid fever,
Year 2
Medium- risk population RR 0.41 (0.29 to 0.57) 76,296
(3 studies)
⊕⊕⊕©
Moderatea,b,d,e
Due to imprecision
Cases of typhoid fever
are probably reduced
with vaccinat ion
4 per 10,000 2 per 10,000
(1 to 2)
High- risk population
59 per 10,000 24 per 10,000
(17 to 34)
4
V
a
c
c
in
e
s
fo
r
p
re
v
e
n
tin
g
ty
p
h
o
id
fe
v
e
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Cases of typhoid fever,
Year 3
Medium- risk population RR 0.44 (0.25 to 0.76) 76,296
(3 studies)
⊕⊕⊕©
Moderatea,b,d,e
Due to imprecision
Cases of typhoid fever
are probably reduced
with vaccinat ion
4 per 10,000 2 per 10,000
(1 to 3)
High- risk population
59 per 10,000 26 per 10,000
(15 to 45)
Cumulative cases of ty-
phoid fever at 2.5 to 3
years
Medium- risk population RR 0.50 (0.39 to 0.65) 235,239
(4 studies)
⊕⊕⊕©
Moderatea,b,d,f
Due to imprecision
Cases of typhoid fever
are probably reduced
with vaccinat ion
4 per 10,000 2 per 10,000
(2 to 3)
High- risk population
59 per 10,000 30 per 10,000
(23 to 38)
* The incidence of typhoid in a medium -risk sett ing is taken f rom the control group in a study f rom China (Yang 2001 CHN).The incidence of typhoid in a high-risk sett ing is
taken f rom a study in India (Sur 2009 IND). This is consistent with the incidence levels described by a global epidemiological study (Crump 2004).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aNo serious risk of bias detected.
bNo serious indirectness detected: studies based in Chile, Indonesia, and Egypt.
cNo serious inconsistency I2 = 33%.
dDowngraded for imprecision: cluster-adjusted trials added, est imated ICC = 0.0015 (f rom Sur 2009 IND).
eNo serious inconsistency, no heterogeneity I2 = 0%.
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f There is moderate heterogeneity (I2 = 50%), which is not explained by strat if ying into type of preparat ion. However, the
CIs fall within a clinically important threshold, meaning the heterogeneity is unlikely be clinically signif icant, so we have not
downgraded for this.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Epidemiology
Typhoid fever is a systemic infection caused by the Gram-negative
bacterium Salmonella enterica serovar Typhi (S. Typhi). S. Typhi
spreads by food, drink, or water contaminated by faecal or urinary
carriers excreting the bacteria. Typhoid fever, also called enteric
fever, remains an important global public health problem. Esti-
mating disease burden is difficult for a number of reasons, includ-
ing the poor sensitivity of diagnostic tests and lack of surveillance
in countries with suspected high prevalence (Andrews 2015). In
2010 there were an estimated 20.6 million cases of typhoid fever
in low- and middle-income countries, with 223,000 deaths (al-
though after adjusting for risk factors and corrected diagnostic
testing, the estimate dropped to 11.9 million cases and 129,000
deaths; Mogasale 2014). This lack of robust data makes decision-
making on priorities and resource allocation difficult andmay neg-
atively impact investment in typhoid fever (Crump 2015).
The highest burden of typhoid fever is thought to be in South Asia
(Wain 2015). Typhoid fever incidence in sub-Saharan Africa has
historically been poorly described; but the recent Typhoid Surveil-
lance in Africa programme, funded by the Gates Foundation, has
shown that incidence in many African countries may be as high
as that in Asia (Steele 2016). Typhoid fever is rare in industrial-
ized nations, although travellers to endemic countries are at risk
of acquiring the disease, with a recent survey naming it the sec-
ond most common potentially life threatening infectious disease
in travellers (Jensenius 2013).
Until recently, the common view was that typhoid fever mainly
affects children of school age and adults. However, experts now
recognize that typhoid fever is an important cause of morbidity
among younger children in areas of high incidence (Ochiai 2008;
Saha 2001; Sinha 1999).
Clinical features
After ingestion of S. Typhi or S. Paratyphi, the bacteria spread
from the intestine via the blood, where they multiply to the in-
testinal lymph nodes, liver, and spleen. Typhoid fever is usually
characterized initially by fever, headache, and abdominal symp-
toms, although other nonspecific symptomsmay occur.Neuropsy-
chiatric manifestations, including psychosis and confusion, may
occur. Other signs include relative bradycardia, rose spots, hep-
atomegaly, and splenomegaly, although these signs are not pathog-
nomonic (Mandell 2005).
Complications occur in 10% to 15% of untreated patients, usually
in the third and fourth weeks of infection. The most important
complications are gastrointestinal bleeding, occurring in up to
10% of patients (Parry 2002), followed by intestinal perforation
and typhoid encephalopathy. Estimates of case-fatality rates in
typhoid fever range from 1% to 4%; fatality rates in children
younger than 4 years of age are 10 times higher than in older
children. In untreated cases, the fatality rates may rise to 10% to
20% (Bhutta 1996).
Both S.Typhi and S.Paratyphi can cause enteric fever, and the clin-
ical manifestations of these two infections are similar. In some areas
enteric fever caused by S. Paratyphi is more common (MacLennan
2014).
Diagnosis and treatment
Confirmation of typhoid fever requires isolating S. Typhi from
blood, bone marrow, stool, or duodenal fluid by culture. The
Widal test, which identifies antibodies against S. Typhi antigens
in blood, has poor sensitivity overall and poor specificity in en-
demic areas (Bhan 2005; Qamar 2015). New-generation, rapid,
serologic tests have been developed, including a dot enzyme-
linked immunosorbent assay test that detects IgM and IgG an-
tibodies against an outer membrane protein of Salmonella Typhi
(Typhidot) and an anti-O9 IgM antibody specific for group D
Salmonellae (Tubex) (Keddy 2011). However, a recent systemic
review found inadequate sensitivity and specificity for these as well
(Thriemer 2013).
Effective and early treatment with antibiotics shortens disease
course and reduces the risk of complications (Kariuki 2015). A
multi-drug resistant (MDR) strain of S. Typhi to chlorampheni-
col, ampicillin and co-trimoxazole emerged in the late 1980s in
Asia, and later in Africa. This has declined with widespread use
of fluoroquinolones. Unfortunatley, S. Typhi strains with reduced
sensitivity and resistance to fluoroquinolones developed in the
1990s, mainly in the Indian subcontinent (Wain 2015). Third
generation cephalosporins (such as ceftriaxone and cefotaxime) are
often used, particularly in patients admitted to hospital. Sporadic
reports of emerging resistance to these antibiotics is of serious con-
cern (Kariuki 2015). Azithromicyn is being used increasingly as a
first-line oral treatment option.
Potential control measures
Given the route of transmission and the fact that humans are the
only source of infection, improved sanitation and food hygiene are
important control measures. However, these measures are associ-
ated with socioeconomic progress, which has been slow in most
endemic areas. Furthermore, achieving control of typhoid fever by
antimicrobial treatment alone requires well-functioning medical
services and is hindered by the increasing problem of antibiotic-
resistant S. Typhi. Therefore vaccination against typhoid fever is
a key control measure in high-risk areas (WHO 2008). In addi-
tion to the populations residing in areas in which typhoid fever is
endemic, travellers to these regions as well as household contacts
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of typhoid fever carriers and laboratory workers may benefit from
an effective vaccine (Parry 2002).
Description of the intervention
Vaccination against typhoid fever is a key control measure; how-
ever, despite their evaluation in populations in endemic low- and
middle- income countries, travellers from high-income countries
are the primary users of typhoid fever vaccines. This situation is
changing, thanks to the availability of high-quality burden of dis-
ease data from endemic countries (Ochiai 2008); to the experience
of typhoid vaccination programmes in Thailand, China, Vietnam,
and India (DeRoeck 2008); and to vaccine demonstration projects
in five Asian countries (Ochiai 2007). A 2008 World Health Or-
ganization (WHO) position paper on the use of typhoid vaccines
concluded that given the continued high burden of disease and
increasing antibiotic resistance, countries should consider the pro-
grammatic use of typhoid vaccines for controlling endemic disease
(WHO 2008). Despite this recommendation, very few typhoid
endemic countries have implemented a typhoid vaccination pro-
gramme (Maurice 2012). Up until recently, there were no typhoid
vaccines effective for children younger than two years, who carry a
large disease burden in developing countries. More recently, newer
typhoid conjugate vaccines (TCV) have entered use, with evidence
of immunogenicity in children from six months old. These show
a potential for inclusion in the infant expanded programme on
immunization (Date 2015).
The following typhoid vaccines have been developed.
Inactivated whole-cell typhoid vaccine
Although vaccines of this type were introduced in 1896 (WHO
2005), their efficacy was established only in 1960 in controlled
trials in Yugoslavia, the Soviet Union, Poland, and Guyana. The
1998 version of this Cochrane Review demonstrated that two
doses of this type of vaccine resulted in 73% efficacy over three
years (95% confidence interval (CI) 65% to 80%) (Engels 1998a).
Different methods of inactivating S. Typhi cells have been used to
prepare these vaccines: acetone-inactivated, alcohol-inactivated or
heat-inactivated and phenol preserved. In field trials, the vaccine
has been associatedwith fever and systemic reactions in 9% to 34%
of recipients, and with short absences from work or school in 2%
to 17% of cases (WHO 2000). Therefore, the inactivated whole-
cell typhoid vaccine is considered unsuitable for use as a public
health vaccine, and, although licensed, it is no longer available for
use (Garmory 2002). Consequently, we have not included killed
whole-cell vaccines in this update.
Ty2la vaccine
Ty21a is a live oral vaccine derived from an attenuated strain of
S. Typhi, approved for use in children aged six years or older. It is
available as an enteric-coated capsule and is given in three doses
(four doses in North America) every other day. The liquid formu-
lation, which was approved in children over two years old, is not
currently available (WHO 2018b). It elicits protection that starts
10 to 14 days after the third dose. Travellers should be revacci-
nated every three to five years with continued or repeat exposure
and those living in disease endemic areas every three years. A the-
oretical question associated with the Ty21a vaccine is whether it
reverts to virulence; however, none of the multiple large field trials
conducted have documented such hypothetical effects, which are
considered exceptionally unlikely given the degree of attenuation
(WHO 2008).
M01ZH09 vaccine
A human challenge trial has assessed a new live attenuated oral
typhoid vaccine, M01ZH09 (Darton 2016). M01ZH09 is con-
structed from a parent Ty2 strain. Following vaccination with
M01ZH09 or placebo in a double-blind randomized trial, partic-
ipants were artificially infected with S. Typhi. A single dose was
not found to be effective in preventing infection (RR 1.81, 95%
CI 0.66 to 5). However, as this was a human challenge, its clinical
effects remain unknown.
Vi polysaccharide vaccine
Vi polysaccharide is based on a purified capsular polysaccharide
of S. Typhi Vi antigen (Date 2015). Given in a single parenteral
dose, protection begins seven days after injection, with maximum
protection achieved at 28 days, when the highest antibody concen-
tration is attained (Garmory 2002). This vaccine is approved for
people aged two years and older. It is not immunogenic in younger
children, Revaccination every three years is recommended.
Typhoid conjugate vaccines
Typhoid conjugate vaccines (TCV) are injectable subunit vaccines
where Vi capsular polysaccharide antigen is linked to a protein
carrier (Date 2015).
Vi-rEPA, a modified Vi vaccine conjugated to a nontoxic recom-
binant Pseudomonas aeruginosa exotoxin A (rEPA), is given as two
parenteral doses. Although theoretically immunogenic from six
months old, it has only been used in children over two years (Lin
2001 VNM). This vaccine has not been commercialized.
Vi-TT, a new conjugated Vi-polysaccharide linked to tetanus tox-
oid carrier protein, has been licensed in India in two preparations:
Peda Typh (two doses, children six months and above;Mitra 2016
IND) andTypbar-TCV (one dose, children sixmonths and above;
Jin 2017;Mohan 2015).WHO has approved Typbar-TCV for in-
fants and children over six months of age in endemic areas (WHO
2018a).
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Why it is important to do this review
This update of the 2014 Cochrane Review, Anwar 2014, provides
an updated assessment of the efficacy and safety of vaccines to
prevent typhoid fever by incorporating data from new trials and
vaccines and incorporating cluster-randomized controlled trials in
the meta-analyses.
O B J E C T I V E S
To assess the effects of vaccines for preventing typhoid fever.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
Adults and children.
Types of interventions
Intervention
Vaccines against S. Typhi include the following.
• Live oral vaccine Ty2la or genetic modifications of this
strain.
• Vi polysaccharide vaccine.
• Conjugate vaccines.
Control
• No vaccine, placebo or typhoid-inactive agents (vaccine for
a different disease)
• Other typhoid vaccines
For the secondary outcome of adverse events, we included only
placebo-controlled trials.
Excluded interventions
We excluded studies focusing on the following types of interven-
tions.
• Trials that evaluated killed whole-cell vaccines, because
these vaccines are no longer in use.
• Trials that reported only on immunogenicity.
• Trials that assessed only adverse events but not clinical
efficacy of vaccines that have not yet been evaluated for clinical
efficacy.
• Human challenge studies where participants were
artificially infected withS. Typhi at a certain time point following
vaccination, since the bacterial inoculum in challenge trials is
constant and the timing of infection relative to vaccination is
highly controlled compared to the real life situation. We
therefore believe these trials to be less relevant for clinicians and
policy-making.
Types of outcome measures
Primary outcomes
Typhoid fever
Typhoid fever defined by isolation of S.Typhi fromblood cultures.
Secondary outcomes
Adverse events
• Serious adverse events, defined as leading to death,
requiring inpatient hospitalization or prolonged existing
hospitalization, life threatening, or resulting in persistent or
significant disability or incapacity.
• Other adverse events, including fever, erythema at injection
site, vomiting, and diarrhoea.
When the occurrence of adverse events was reported after each
of several doses, we extracted the occurrence following each dose
separately. When reports provided estimates of the incidence of
adverse events for different time points after vaccination, we pre-
sented the data corresponding to 24 hours after vaccination.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
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Databases
We searched the following databases using the search terms
and strategy described in Appendix 1: Cochrane Infectious Dis-
eases Group Specialized Register (searched 14 February 2018);
Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library (2018, Issue 2 of 12); MED-
LINE (1966 to 14 February 2018); Embase (1974 to 14 February
2018); and LILACS (1982 to 14February 2018).We also searched
themetaRegister of Controlled Trials (mRCT) using ‘typhoid’ and
‘vaccine’ as search terms (searched 14February 2018).We searched
the Internet for new drug application (NDA) documents of the
US Food and Drug Administration, which may include unpub-
lished studies (last accessed 14 February 2018).
Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: International Conference on Typhoid and other Invasive
Salmonelloses (2013 to 2017); Interscience Conference on An-
timicrobial Agents and Chemotherapy (ICAAC/ASM Microbe;
1995 to 2017); European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID; 2001 to 2017); and the Annual
Meeting of the Infectious Diseases Society of America (IDSA;
2001 to 2017).
Reference lists
We examined the reference lists of the included trials.
Data collection and analysis
Selection of studies
Two review authors independently inspected titles and abstracts
identified by the literature search to identify potentially relevant
publications, retrieving the full text of any record that at least
one review author judged as potentially relevant. We applied the
inclusion criteria for the final decision regarding eligibility. We
also ascertained that trials were independent, that is, we looked
for multiple publications of the same trial and made sure that
we included each trial only once. If a single included reference
includedmore than one trial, we labelled the trials separately using
a letter (for example, Wahdan 1980a EGY and Wahdan 1980b
EGY). We resolved disagreements by discussion and consensus,
documenting reasons for excluding studies from the review. We
attempted to contact trial authors for clarification if it was unclear
whether a potentially relevant trial was eligible for the review.
Data extraction and management
Two review authors independently extracted data into a standard
form; a third review author extracted the data in cases of disagree-
ment. One review author entered data into RevMan 5 (RevMan
2014).
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias in in-
cluded trials; in cases of disagreement, we consulted a third review
author. We took an individual component approach to quality as-
sessment by using five variables: generation of allocation sequence;
allocation concealment; blinding of participants and investigators;
inclusion of all randomly assigned participants in the analysis; and
reporting of all stated outcomes. We categorized generation of the
allocation sequence and allocation concealment as adequate, un-
clear, or inadequate by using the approach described in Jüni 2001.
We recorded whether trials used single, double or no blinding, and
whether they reported results for all randomized participants.
Measures of treatment effect
We recorded the number of participants experiencing the event
and the number analysed in each treatment group.We aimed to ex-
tract data according to an intention-to-treat analysis and reported
any discrepancies in the number randomly assigned and the num-
bers analysed in each treatment group. We calculated risk ratios
with 95% CIs, and in cluster-RCTs that reported cluster adjusted
effect estimates, we extracted the reported effects as risk ratios or
hazard ratios.
Unit of analysis issues
For trials randomly assigning clusters, we extracted cluster-ad-
justed effect estimates when available. We also recorded the num-
ber of clusters in the trial, the average size of clusters, the unit of
randomization (for example, household or institution) and the sta-
tistical methods used to analyse the trial results. For cluster-RCTs
reporting individual patient results without adjustment for clus-
tering, we calculated an intracluster correlation coefficient (ICC)
using trial data from Sur 2009 IND (that allowed calculation of
unadjusted risk ratios from crude number of individuals and re-
ported cluster-adjusted hazard ratios) as 0.0015. We calculated
the design effect of cluster-RCTs that did not adjust for clustering
taking into account average cluster size. We used this design effect
to calculate the effective number of events per control and inter-
vention and the effective number of participants per control and
intervention to be used in the meta-analysis. We present cluster-
unadjusted results in a separate table but do not use them in the
meta-analysis.
If a single included trial compared several vaccine arms with a
control arm, we labelled the arms separately using a Roman nu-
meral (for example, Black 1990i CHL and Black 1990ii CHL).
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To avoid including data for controls more than once in the same
comparison, we divided the placebo group into equal parts while
assuming equal incidence in these groups.
Dealing with missing data
When necessary, we contacted the trial authors for clarification
or additional details regarding trial methodology or results. In
cluster-RCTs, we asked authors for distribution of outcomes in
the different clusters.
Assessment of heterogeneity
We assessed heterogeneity by inspecting the forest plots to detect
overlapping CIs and the I2 statistic used to denote levels of hetero-
geneity as defined in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
• 0% to 40% heterogeneity: might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We planned to inspect funnel plots to assess small study effects
and explore the possibility of reporting bias. However, all analyses
included too few trials to analyse the funnel plot.
Data synthesis
We conducted separate meta-analyses for each vaccine type. We
combined dichotomous data from trials that randomly assigned
individuals or corrected numbers from cluster-RCTs that did not
adjust by using risk ratios (RRs) with 95% CIs. In analyses includ-
ing cluster-RCTs that reported adjusted risk ratios, we pooled risk
ratios from all the trials using inverse variance meta-analysis. We
interpreted the results as efficacy, defined as 1− RR and expressed
as a percentage. We analysed efficacy per year and cumulative effi-
cacy, as they provide different information. Analyses per year show
whether the effect of the vaccine decreases over time, and cumula-
tive efficacy demonstrates efficacy overall, for a given period up to
three years and longer if available, regardless of whether changes
over time occurred within this period. We rounded to the nearest
year when trials included follow-up for only part of a year. The
random-effects model was used throughout the review. We cal-
culated number needed to treat for an additional beneficial out-
come (NNTB) (1/reduction in risk of typhoid fever attributable
to vaccination) for each type of vaccine based on the cumulative
2.5 to 3-year point estimate and the incidence of typhoid fever in
control groups of trials assessing the given vaccination.
Subgroup analysis and investigation of heterogeneity
We had planned to explore the following potential sources of het-
erogeneity in subgroup analyses: number of doses; length of fol-
low-up; type of oral formulation in the Ty21a vaccine (capsules
and type of capsule, liquid formulation) and age. However, data
were sparse, so we present only the subgroup by type of oral for-
mulation in the meta-analyses.
Sensitivity analysis
We conducted sensitivity analyses by limiting the meta-analysis to
trials at low of risk of bias due to randomization methods for the
primary outcome and assessing whether vaccine efficacy changed.
We considered that blinding would not affect bias for our pri-
mary outcome of typhoid fever cases, as this measure is objective
(Savovi 2012).
‘Summary of findings’ table
We assessed the certainty of the evidence across each outcomemea-
sure using theGRADE approach. The certainty rating across stud-
ies has one of four levels: high, moderate, low or very low. GRADE
initially classifies randomized trials as high certainty, downgrad-
ing may be warranted after assessment of five criteria: risk of bias,
consistency, directness, imprecision, and publication bias (Guyatt
2008). The ‘Summary of findings’ tables present the main results
of the review and the certainty assessments.
R E S U L T S
Description of studies
Results of the search
We present the search results in a PRISMA study flow diagram in
Figure 1. In the previous version of this review, Anwar 2014, we
included 32 publications of 19 trials (the previous version misre-
ported this number, but we have corrected it in the update). We
excluded one study that was in the previous review, Thiem 2011,
due to the refining of the inclusion criteria for adverse events trials.
We updated the literature search to 14 February 2018 and iden-
tified 50 new unique records. We assessed 13 full-text articles for
eligibility after abstract screening. One new trial met the inclusion
criteria (Mitra 2016 IND), while three trials were ongoing (see
the Characteristics of ongoing studies section).
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Figure 1. Study flow diagram.
Included studies
In total, 32 records reporting on 19 trials (12 RCTs randomizing
individuals and 7 cluster-RCTs) met the inclusion criteria: see de-
tails in Characteristics of included studies table. The 2018 review
update includes one new trial evaluating the efficacy of Vi polysac-
charide conjugated to tetanus toxoid vaccine (Vi-TT), PedaTyph
(Mitra 2016 IND).
All of the trials except Keitel 1994 USA took place in countries
where typhoid fever is endemic: Chile (four trials), China (three
trials), Vietnam (one trial), Thailand (two trials), Pakistan (one
trial), Egypt (one trial), India (two trials), Indonesia (one trial),
Nepal (one trial), and South Africa (one trial). None of the trials
evaluated vaccine efficacy in travellers from developed countries
or compared the efficacy of different types of typhoid vaccines.
Participants ranged in age across the trials. Three trials included
children aged under 12 years only (Lin 2001 VNM; Mitra 2016
IND;Wahdan 1980a EGY), and one trial reported on adults only
(Levine 1986i CHL). Only three efficacy trials included data on
adults over 25 years of age (Acharya 1987 NPL; Simanjuntak
1991i IDN;Wang 1997 CHN). None of the trials reported on use
of typhoid vaccination in adults aged over 55 years. Only one trial
included children under two years of age (Mitra 2016 IND). All
trials either excluded pregnant participants or included no details
on their inclusion.
Outcomes
Data on the primary outcome, cases of typhoid fever, were derived
from 13 trials.
• Five trials of Ty21a (Black 1990i CHL; Black 1990ii CHL;
Levine 1987i CHL; Levine 1987ii CHL; Levine 1987iii CHL;
Levine 1987iv CHL; Levine 1990i CHL; Levine 1990ii CHL;
Simanjuntak 1991i IDN; Simanjuntak 1991ii IDN; Wahdan
1980a EGY).
• Six trials of Vi polysaccharide (Acharya 1987 NPL; Khan
2012 PAK; Klugman 1987 ZAF; Sur 2009 IND; Wang 1997
CHN; Yang 2001 CHN).
• One Vi-rEPA trial (Lin 2001 VNM).
• One Vi-TT (PedaTyph) trial (Mitra 2016 IND).
Data on the secondary outcome, adverse events, came from nine
trials.
• Five trials of Ty21a (Levine 1986i CHL; Levine 1986ii
CHL; Olanratmanee 1992 THA; Wahdan 1980a EGY; Wahdan
1980b EGY; Simanjuntak 1991i IDN; Simanjuntak 1991ii
IDN).
• Three trials of Vi polysaccharide (Keitel 1994 USA; Yang
2001 CHN; Zhou 2007 CHN).
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• One trial of Vi-rEPA (Lin 2001 VNM).
One additional individual RCT assessed the Ty21a vaccine and
reported on adverse events but did not provide the number of
participants per study arm (Cryz 1993 THA); therefore we do not
include results of this trial in the meta-analysis.
Excluded studies
In this 2018 update we excluded nine trials. Across all versions
of this review, we excluded 60 publications (53 trials). For de-
tails of excluded trials and reasons for their exclusion, see the
Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 for a summary of the ‘Risk of bias’ assessment and
the Characteristics of included studies for further details on the
reasons for review authors’ judgements.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six of the 13 trials reporting on efficacy reported low-risk ran-
domization procedures (Khan 2012 PAK; Mitra 2016 IND;
Simanjuntak 1991i IDN; Simanjuntak 1991ii IDN; Sur 2009
IND;Wang 1997 CHN; Yang 2001 CHN). The other seven trials
did not provide enough information to permit judgement. All but
one trial, Klugman 1987 ZAF, used low-risk methods to conceal
allocation.
Three of the 10 trials reporting adverse events described
low-risk randomization procedures (Simanjuntak 1991i IDN;
Simanjuntak 1991ii IDN; Yang 2001 CHN; Zhou 2007 CHN).
Likewise, three used low-risk methods to conceal allocation (Lin
2001 VNM; Simanjuntak 1991i IDN; Simanjuntak 1991ii IDN;
Yang 2001 CHN). The other trials did not report enough infor-
mation to permit judgement.
Blinding
All but 3 of the 13 trials on clinical efficacy used double-blinding.
Two cluster-randomized trials could not guarantee blinding of re-
searchers or participants, as they used vaccines that were packaged
differently and therefore did not look identical (Khan 2012 PAK;
Sur 2009 IND). However, both trials tried to minimize this effect
by assigning each vaccination team to only one vaccine, identify-
ing the vaccines only by code, and not informing local research
staff members or participants of the assignment of the code or
the vaccine. One cluster-randomized trial, Mitra 2016 IND, was
open label with no placebo arm, with the control group having
vaccinations as per the normal schedule. There is no information
as to whether researchers were blinded.
All of the trials that included adverse effects used double-blinding.
Incomplete outcome data
Ten of 13 trials that investigated vaccine efficacy included all ran-
domly assigned participants in the analysis, so we classified them
at low risk of attrition bias. Three trials provided no reasons for
missing data (Black 1990i CHL; Black 1990ii CHL; Levine 1987i
CHL; Levine 1987ii CHL; Levine 1987iii CHL; Levine 1987iv
CHL; Levine 1990i CHL; Levine 1990ii CHL).
We assessed 5 of 10 trials that included adverse events as being at
low risk in terms of including all randomly assigned participants
in the analysis or providing reasons for missing outcome data.
Two trials were unclear on this issue (Cryz 1993 THA; Levine
1986i CHL; Levine 1986ii CHL). We judged the trial that did
not provide the number of participants per study arm as being at
high risk of attrition bias (Cryz 1993 THA).
Selective reporting
All but one of the 13 trials on vaccine efficacy reported on pre-
planned outcomes, meriting a classification of low risk of bias.
Mitra 2016 IND did not report on paratyphoid outcomes as the
prospectively registered protocol had described, so we classified
it as being at high risk of bias. The vaccine assessed would not
have affected the incidence of S. Paratyphi infections but would
have aided us to judge whether the decreased number of infections
was due to the effect of the vaccine or consequences of better
socioeconomic status of the immunized group (see other sources
of bias described below).
All 10 trials included in the adverse events analysis reported on
plausible outcomes, so we classified them as being at low risk of
bias, even though protocols were not available.
Other potential sources of bias
Four of the seven cluster-RCTs on vaccine efficacy provided data
on the efficacy of the Ty21a vaccine (Black 1990i CHL; Levine
1987i CHL; Levine 1990i CHL; Wahdan 1980a EGY). These
four cluster-RCTs, all of which randomly assigned by classroom,
did not adjust for clustering in their results.
Two of the vaccine efficacy cluster-RCTs provided data on the
efficacy of the Vi polysaccharide vaccine (Khan 2012 PAK; Sur
2009 IND). Both of these trials randomly assigned geographic
clusters. Study authors providedunpublished cluster-adjusted data
for the meta-analysis.
The remaining vaccine efficacy cluster-RCT provided data on the
efficacy of the Vi-TT conjugate vaccine PedaTyph (Mitra 2016
IND). The trial cluster-randomized children by school and did not
adjust for clustering in the sample size calculations or in results.
The intervention and control groups were different in terms of so-
cioeconomic data, despite randomization, with lower status in the
control group. As typhoid fever is associated with poor sanitation
and hygiene, it is plausible that the vaccine would prevent more
cases in lower socioeconomic groups. Although the authors did
not mention it in the published paper, according to the prospec-
tively registered protocol the company who manufactures Peda
Typh funded the study. We classified this trial as being at high risk
of other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Ty21a
vaccine (three doses) versus control for preventing typhoid fever;
Summary of findings 2 Vi polysaccharide vaccine (1 dose) versus
control for preventing typhoid fever; Summary of findings 3 Vi-
rEPA vaccine (2 doses) versus control for preventing typhoid fever;
Summary of findings 4 Vi-TT conjugate vaccine (PedaTyph) (2
doses) versus control for preventing typhoid fever
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TY21a vaccine
Efficacy
Investigators assessed the TY21a vaccine in one four-arm indi-
vidual RCT, Simanjuntak 1991i IDN, and four cluster-RCTs, re-
ported in Black 1990ii CHL Levine 1987i CHL Levine 1987ii
CHLLevine 1987iii CHLLevine 1987iv CHLLevine 1990i CHL
Levine 1990ii CHL and Wahdan 1980a EGY. The cluster-RCTs
did not adjust analyses for the effect of clustering, so they may
have overestimated any protective effect. We adjusted results from
these trials using an estimated ICC of 0.0015 and average clus-
ter size to calculate the design effect so we could include them in
the meta-analysis. Table 1 displays adjusted results, and we refer
to these findings unless otherwise specified. Table 2 shows unad-
justed results.
A three-dose schedule of Ty21a vaccine provided vaccine efficacy
of 45% at year 1 (95% CI 14% to 65%; 76,296 participants;
Analysis 1.1), 59% at year 2 (95% CI 43% to 71%; 76,296 par-
ticipants; Analysis 1.2) and 56% at year 3 (95% CI 24% to 75%;
76,296 participants; Analysis 1.3). The cumulative efficacy of the
Ty21a vaccine over 2.5 to 3 years was 50% (95% CI 35% to 61%;
235,239 participants; Analysis 1.4).
Cumulative efficacy of the three-dose schedule ofTy21a vaccine for
over three years is available from two of the adjusted cluster-RCTs
(Levine 1987ii CHL; Levine 1990i CHL). Cumulative efficacy
was 77% at five years (95% CI 60% to 86%; Table 1) and 63%
at seven years (95% CI 42% to 76%; Table 1).
We were unable to conduct subgroup analysis by age, as trials
evaluating the efficacy of the Ty21a vaccine did not stratify results
according to this variable.
In the cumulative analysis there is moderate heterogeneity that is
not explained by stratifying results by type of preparation. In di-
rect randomized comparisons between liquid and enteric capsules
(Analysis 2.1) and between enteric and gelatin capsules (Analysis
3.1), the heterogeneity was too high to pool the results, so we were
unable to conduct a meta-analysis.
Adverse events
None of the individual- or cluster-randomized trials reported any
serious adverse events (5 trials, 235,239 participants: Levine 1986i
CHL; Levine 1986ii CHL; Olanratmanee 1992 THA; Wahdan
1980a EGY; Wahdan 1980b EGY; Simanjuntak 1991i IDN;
Simanjuntak 1991ii IDN; Appendix 2).
Compared with placebo, the Ty21a vaccine (both preparations)
did not increase the incidence of vomiting (2 trials, 2066 partic-
ipants; Analysis 4.2), diarrhoea (2 trials, 2066 participants; Anal-
ysis 4.3), nausea or abdominal pain (2 trials, 2066 participants;
Analysis 4.4), headache (1 trial, 1190 participants; Analysis 4.5),
or rash (1 trial, 1190 participants; Analysis 4.6) compared with
control. However, fever was more common after vaccine delivery
(RR 1.84, 95% CI 1.02 to 3.05; 2 trials, 2066 participants). A
pooled analysis of two individual-RCTs showed a marginal in-
crease in risk of any mild adverse events (RR 1.67, 95% CI 1.03
to 2.72; 2 trials, 1360 participants; Analysis 4.7).
The cluster-randomized studiesWahdan 1980a EGY andWahdan
1980b EGY reported adverse events per dose of vaccine rather than
per patient, so we could use these data in the meta-analysis. There
appeared to be more episodes of vomiting and nausea/abdominal
pain per dose with the vaccine, but the overall incidence was low
(0.1% vomiting with Ty21a versus 0.05% with placebo; 0.03%
nausea/abdominal pain with Ty21a versus 0.004% with placebo,
Appendix 2).
Cryz 1993 THA did not supply the number of participants in
the vaccine and placebo groups, so results could not be analysed.
Authors noted that all reactions were mild.
See Summary of findings for the main comparison.
Vi polysaccharide vaccine
Efficacy
Four individually randomized RCTs assessed the efficacy of this
vaccine (Acharya 1987 NPL; Klugman 1987 ZAF; Wang 1997
CHN; Yang 2001 CHN), as did two cluster-RCTs (Khan 2012
PAK; Sur 2009 IND). We obtained cluster-adjusted results for
efficacy at year 2 following vaccination from the study authors, so
we were able to pool the results from the individually randomized
RCTs and the cluster-adjusted RCTs using the generic inverse
variance method.
The efficacy of the Vi polysaccharide vaccine was 69% at year 1
(95% CI 63% to 74%; 3 trials, 99,797 participants; Analysis 5.1)
and 59% at year 2 (95% CI 45% to 69%; 4 trials, 194,969 par-
ticipants; Analysis 5.1) There was high heterogeneity in year 2 (I2
= 72%), which we were unable to explain with subgroup analysis.
Ty21a efficacy was 50% at year 3 based on a single trial (95%
CI 22% to 68%; 11,384 participants; Analysis 5.1). Cumulative
efficacy at 2.5 to 3 years, based on the same single trial (Klugman
1987 ZAF), was 55% (95%CI 30% to 70%; 11,384 participants;
Analysis 5.2).
Two of the trials used the Widal test (as well as a positive culture)
to detect cases of typhoid fever (Wang 1997 CHN; Yang 2001
CHN). Results of the Widal test were not included in the meta-
analysis. Both trials followed participants for six years, and their
combined culture-based results demonstrated that protection was
significant in each of the first two years but not in years 3 or 6.
Three-year cumulative efficacy was 69% (95% CI 50% to 81%),
and combined efficacy for years 4 through 6 was 11% (95% CI
−76% to 55%) (analyses not shown).
Three of the RCTs conducted subgroup analysis by age: Yang
2001CHNused individual randomization,whileKhan 2012 PAK
and Sur 2009 IND were cluster trials. However, the individually
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based RCT included very small numbers in each age group (Yang
2001 CHN); the two cluster-RCTs did not adjust for clustering
and presented their results in the form of hazard ratios rather
than risk ratios (with effectiveness of vaccination estimated as:
(1 − hazard ratio) × 100% (Khan 2012 PAK; Sur 2009 IND).
We were therefore unable to conduct subgroup analysis by age.
Table 3 presents unadjusted results by age from the two cluster-
RCTs. The cluster-randomized trial conducted in India, Sur 2009
IND, found that two years after vaccination, the Vi polysaccharide
vaccine provided significantly more protection than the control
condition for children two to five years of age (efficacy 82%, 95%
CI 58% to 92%). However, contrary to these results, the cluster-
randomized trial conducted in Pakistan, Khan 2012 PAK, showed
no protection among children between two and five years of age
compared with placebo at two years after vaccination (efficacy
−30%, 95% CI −183% to 40%).
Adverse events
No trials reported on serious adverse events.
Overall, we did not find a significant difference between vaccine
and placebo in the incidence of fever (3 trials, 132,261 partici-
pants; Analysis 6.1) or erythema (3 trials, 132,261 participants;
Analysis 6.2). However, swelling (RR 6.06, 95%CI 1.07 to 34.22;
3 trials, 1767 participants; Analysis 6.3) and pain at the injection
site (RR 7.98, 95% CI 3.69 to 17.24; 1 trial, 667 participants;
Analysis 6.4) were more common after delivery of the Vi polysac-
charide vaccine.
See Summary of findings 2.
Vi-rEPA vaccine
Efficacy
One trial in children aged two to five years, conducted in Viet-
nam, evaluated the efficacy of this vaccine (Lin 2001 VNM), re-
porting that it was 94% at year 1 (95% CI 75% to 99%; 12,008
participants; Analysis 7.1) and 87% in year 2 (95% CI 56% to
96%; 12,008 participants; Analysis 7.1), with a two-year cumula-
tive efficacy of 91% (95% CI 78% to 96%; 12,008 participants;
Analysis 7.1). The cumulative efficacy of the Vi-rEPA vaccine after
3.8 years was 89% (95% CI 77% to 95%; 12,008 participants,
Analysis 7.1). The planned vaccine schedule was two doses of vac-
cine approximately six weeks apart. Although 388 children in the
vaccine group received only one dose of vaccine instead of two,
authors still analysed them along with those who had received two
doses. The cumulative two-year efficacy for two doses of vaccine
was the same as for one or two doses of vaccine, so this did not
seem to undermine the validity of the results.
No trials assessed the efficacy of this vaccine in children older than
five or in adults.
Adverse events
One trial evaluated adverse events associated with this vaccine, re-
porting no serious events (Lin 2001 VNM). Fever was more com-
mon following delivery of both the first and second vaccinations
with Vi-rEPA compared with placebo (dose 1: RR 2.54, 95% CI
1.69 to 3.82, 12,008 participants, 1 trial, Analysis 8.1; dose 2: RR
4.39, 95% CI 2.85 to 6.77, 11,091 participants, 1 trial, Analysis
8.2). After the first dose of Vi-rEPA, no participants in either the
test or placebo group reported erythema or swelling at the injec-
tion site (Analysis 8.3; Analysis 8.5). After the second dose, there
was no significant difference between the vaccine and placebo for
erythema (Analysis 8.4), but swelling at the injection site was more
common in the Vi-rEPA group (RR 20.15, 95%CI 2.71 to 150.8;
11,091 participants, 1 trial; Analysis 8.6).
See Summary of findings 3.
Vi-tetanus toxoid conjugated typhoid vaccine
(Pedatyph)
Efficacy
One cluster-randomized trial in children aged six months to 12
years of age assessed the efficacy of this vaccine in India (Mitra
2016 IND). The authors did not adjust for cluster randomization.
Using an estimated ICC of 0.0015 (from Sur 2009 IND) and an
average cluster size of 135, we calculated the design effect as 1.201
and adjusted results accordingly. Table 4 shows unadjusted results.
The adjusted efficacy of Vi-TT (PedaTyph, 2 doses) at one-year
follow-up was 94% (95% CI −1% to 100%; 1625 participants;
Analysis 9.1).
Adverse effects
The trial did not report any serious adverse effects.
See Summary of findings 4.
Heterogeneity
Other than where already stated, in most comparisons that in-
cluded several trials, the degree of heterogeneity was not substan-
tial (that is, I2 statistic < 50% and Chi2 test with P value > 0.10).
However, because of the limited number of trials included in each
comparison, we were unable to identify the reason for the greater
degree of heterogeneity in some comparisons.
Sensitivity analyses
Weperformed sensitivity analyses for trials with a split control arm
in the main analyses and found that the results did not change
(analyses not shown). As most comparisons included few trials,
we could not perform sensitivity analyses according to risk of bias.
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We did not notice any difference in adverse event results from
trials that did and did not evaluate efficacy, although we did not
undertake formal testing.
Number needed to treat for an additional beneficial
outcome (NNTB) to prevent one case of typhoid
fever
Ty21a vaccine
The liquid formulation of the Ty21a vaccine had a three-year cu-
mulative protective efficacy of 71% (95% CI 34% to 88%; Levine
1990i CHL; Simanjuntak 1991i IDN;Wahdan 1980a EGY;Anal-
ysis 1.4). The incidence rate in the control groupwas 544/100,000
with a corresponding NNTB of 259 (95% CI 209 to 541). The
enteric capsule formulation of the Ty21a vaccine had three-year
cumulative protective efficacy of 46% (95% CI 32% to 58%;
Levine 1987i CHL; Levine 1987ii CHL; Levine 1990ii CHL;
Simanjuntak 1991ii IDN; Analysis 1.4). The incidence in the con-
trol group was 734/100,000, and the corresponding NNTB was
296 (95% CI 235 to 426).
Vi polysaccharide vaccine
The Vi polysaccharide vaccine has a 2.5- to 3-year cumulative
protective efficacy of 55% (95% CI 30% to 70%; Klugman 1987
ZAF; Analysis 4.2), with an incidence rate of 1160/100,000. From
these data, we estimated the NNTB to be 157 (95% CI 1234 to
287).
18Vaccines for preventing typhoid fever (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vi polysaccharide vaccine (1 dose) versus control for preventing typhoid fever
Patient or population: adults and children of 2 years of age and older
Settings: any
Intervention: Vi polysaccharide vaccine (1 dose)
Comparison: control; ef f icacy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Control; efficacy Vi polysaccharide vac-
cine (1 dose)
Incidence of typhoid
fever - year 1
Blood culture
Moderatea RR 0.31
(0.26 to 0.37)
99,797
(3 studies)
⊕⊕⊕⊕
Highb,c,d,e
Reduces incidence of
typhoid fever
4 per 10,000 1.2 per 10,000
(1.0 to 1.5)
Higha
59 per 10,000 18.29 per 10,000
(15.34 to 21.83)
Incidence of typhoid
fever - year 2
Moderatea RR 0.41
(0.31 to 0.55)
194,969
(4 studies)
⊕⊕⊕©
Moderateb,f,g,e
Due to inconsistency
Probably reduces inci-
dence of typhoid fever
4 per 10,000 1.6 per 10,000
(1.2 to 2.2)
Higha
59 per 10,000 24.19 per 10,000
(18.29 to 32.45)
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Incidence of typhoid
fever -year 3
Moderatea RR 0.5
(0.32 to 0.78)
11,384
(1 study)
⊕⊕©©
Lowh,i
Due to imprecision and
indirectness
May reduce incidence
of typhoid fever
4 per 10,000 2 per 10,000
(1.28 to 3.12)
Higha
59 per 10,000 29.5 per 10,000
(18.88 to 46.02)
Cumulative cases of ty-
phoid fever at 2.5 to 3
years
Moderatea RR 0.45 (0.30 to 0.70) 11,384
(1 study)
⊕⊕©©
Lowh,i
Due to imprecision and
indirectness
May reduce incidence
of typhoid fever
4 per 10,000 1.8 per 10,000
(1.2 to 2.8)
Higha
59 per 10,000 26.55 per 10,000 (17.7
to 41.3)
Serious adverse events No serious adverse events reported
Fever 5 per 1000 5 per 1000
(4.2 to 5.7)
RR 0.98
(0.84 to 1.13)
132,261
(3 studies)
⊕⊕⊕©
Moderateb,c,k,l
Due to imprecision
Probably lit t le or no as-
sociat ion with fever
Erythema 5 per 1000 6 per 1000
(2 to 22)
RR 1.15
(0.33 to 4.03)
132,261
(3 studies)
⊕⊕⊕©
Lowb,j,l
Due to imprecision and
inconsistency
May have lit t le or no
associat ion with ery-
thema
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence:
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aThe incidence of typhoid in a medium-risk sett ing is taken f rom the control group in a study f rom China (Yang 2001 CHN).The
incidence of typhoid in a high-risk sett ing is taken f rom a study in India (Sur 2009 IND). This is consistent with the incidence
levels described by a global epidemiological study (Crump 2004).
bNo serious risk of bias detected.
cNo serious inconsistency: The result was consistent across all 3 trials (I2 = 0%).
dNo serious indirectness: the vaccine has been evaluated in trials f rom Nepal, South Af rica and China. Of note, none of the
trials were conducted in travellers f rom nonendemic sett ings, and all three trials excluded children younger than 2 years of
age and pregnant women.
eNo serious imprecision: the result is stat ist ically signif icant with a narrow 95%CI. The meta-analysis is adequately powered
to detect this ef fect.
fDowngraded by 1 level for inconsistency: the magnitude of the protect ive ef fect varied between trials f rom 34% to 69% (I2 =
72%). The reasons for this are not clear; one potent ial factor may be the dif ferent age groups included in the trials, with Khan
2012 PAK suggest ing lower protect ive ef fect in children < 5 years of age.
gNo serious indirectness: the vaccine has been evaluated in trials f rom endemic sett ings (India, Pakistan, China and South
Af rica).
hDowngraded by 1 level for imprecision: wide CIs.
iDowngraded by 1 level for indirectness - only assessed in one trial in South Af rica in children aged 5 to 15 years.
kNo serious indirectness: the vaccine has been evaluated in trials f rom endemic sett ings (China) and in one trial conducted in
a non-endemic sett ing (USA).
lDowngraded by 1 level for serious imprecision: The result is not stat ist ically signif icant.
jDowngraded by 1 level for inconsistency (I2 = 63%).
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Vi- rEPA vaccine (2 doses) versus control for preventing typhoid fever
Patient or population: adults and children of 2 years of age and older
Settings: any
Intervention: Vi-rEPA vaccine (2 doses)
Comparison: control; ef f icacy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Assumed risk Corresponding risk
Control; efficacy Vi- rEPA vaccine (2
doses)
Incidence of typhoid
fever - year 1
Follow-up: 1 year
Moderatea RR 0.06
(0.01 to 0.25)
12,008
(1 study)
⊕⊕⊕©
Moderateb,c
Due to indirectness
Probably reduces inci-
dence of typhoid fever
4 per 10,000 0.24 per 10,000
(0.04 to 1)
Higha
59 per 10,000 3.5 per 10,000
(0.6 to 14.8)
Incidence of typhoid
fever - year 2
Moderatea RR 0.13
(0.04 to 0.44)
12,008
(1 study)
⊕⊕⊕©
Moderatec
Due to indirectness
Probably reduces inci-
dence of typhoid fever
4 per 10,000 0.52 per 10,000
(0.16 to 1.8)
Higha
59 per 10,000 7.7 per 10,000
(2.4 to 26.0)
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Cumulative cases of ty-
phoid fever at 2 years
Moderatea RR 0.09 (0.04 to 0.22) 12,008
(1 study)
⊕⊕⊕©
Moderatec
Due to indirectness
Probably reduces inci-
dence of typhoid fever
4 per 10,000 0.36 per 10,000 (0.16
to 0.88)
Highb
59 per 10,000 5.31 per 10,000 (2.36
to 12.98)
Cumulative cases of ty-
phoid fever at 3.8 years
Moderatea RR 0.11 (0.05 to 0.23) 12,008
(1 study)
⊕⊕⊕©
Moderatec
Due to indirectness
Probably reduces inci-
dence of typhoid fever
4 per 10,000 0.44 per 10,000 (0.2 to
0.92)
Highb
59 per 10,000 6.49 per 10,000
(2.95 to 13.57)
Serious adverse events See comment See comment Not est imable 12,008
(1 study)
See comment No serious adverse
events were reported
Fever after Vi- rEPA
(dose1)
5 per 1000 13 per 1000
(8 to 18)
RR 2.54
(1.69 to 3.62)
12,008
(1 study)
⊕⊕⊕©
Moderated
Due to imprecision
Probably associated
with fever following
vaccinat ion
Fever after Vi- rEPA
(dose2)
4 per 1000 18 per 1000
(11 to 27)
RR 4.39
(2.85 to 6.77)
11,091
(1 study)
⊕⊕⊕©
Moderated
Due to imprecision
Probably associated
with fever following
vaccinat ion
Erythema after Vi- rEPA
(dose 2)
0.2 per 1000 0.4 per 1000
(0.04 to 4.4)
RR 2.01
(0.19 to 22.21)
11,091
(1 study)
⊕⊕©©
Lowd,e
Due to serious impreci-
sion
May have lit t le or no
associat ion with ery-
thema
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Swelling at injection
site after Vi- rEPA
(dose 2)
0.2 per 1000 4 per 1000
(0.5 to 30)
RR 20.15
(2.71 to 150.08)
11,091
(1 study)
⊕⊕⊕©
Moderated
Due to imprecision
Probably associated
with swelling at injec-
t ion site
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence:
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aThe incidence of typhoid in a medium-risk sett ing is taken f rom the control group in a study f rom China (Yang 2001 CHN).
The incidence of typhoid in a high-risk sett ing is taken f rom a study in India (Sur 2009 IND). This is consistent with the
incidence levels described by a global epidemiological study (Crump 2004).
bNo serious risk of bias detected.
cDowngraded by 1 level for indirectness: the vaccine has been evaluated by only one trial in children 2 to 5 years of age in a
high-incidence sett ing (Vietnam).
dDowngraded by 1 level for imprecision: wide 95%CIs.
eDowngraded by 1 level for serious imprecision: the result is not stat ist ically signif icant.
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Vi-TT conjugate vaccine versus control for preventing typhoid fever
Patient or population: children aged 6 months to 12 years
Settings: India
Intervention: Vi-TT (PedaTyph) vaccine (2 doses)
Comparison: control; ef f icacy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence (GRADE)
Comments
Assumed riska Corresponding risk
Control; efficacy Vi-TT conjugate; (2
doses)
Incidence of typhoid
fever - year 1
Follow-up: 1 year
13 per 1000 0.8 per 1000
(0 to 13)
RR 0.06b
(0.00 to 1.01)
1625
(1 study)
⊕©©©
Very lowc,d,e
Due to risk of bias, seri-
ous imprecision and in-
directness
We do not know if
this vaccine prevents
typhoid fever
* The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
Abbreviations: CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
aThe basis for the assumed risk is taken f rom the disease incidence in the control group in the trial (M itra 2016 IND).
bPrimary trial is not cluster-adjusted. This est imate uses a small assumed intracluster correlat ion coef f icient of 0.0015
calculated f rom cluster-randomized ViPs vaccine trial Sur 2009 IND, which did adjust for clustering.
cDowngraded by 1 level for risk of bias.
dDowngraded by 1 level for imprecision. Wide CIs that include appreciable harm and few (11 events) in the trial.
eDowngraded by 1 level for indirectness. Only one trial in one sett ing and in children under 12 years.2
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D I S C U S S I O N
Summary of main results
Ty21a vaccine (three doses)
A three-dose schedule of Ty21a vaccine probably prevents around
half of typhoid cases during the first three years after vaccination
(moderate-certainty evidence). These data include patients aged 3
to 44 years.
Comparedwith placebo, this vaccine probably does not causemore
vomiting, diarrhoea, nausea, or abdominal pain, (moderate-cer-
tainty evidence) headache, or rash (moderate-certainty evidence);
however, fever is probably more common following vaccination
(moderate-certainty evidence).
See Summary of findings for the main comparison.
Vi polysaccharide vaccine (one dose)
A single dose of Vi polysaccharide vaccine prevents around two-
thirds of typhoid cases in the first year after vaccination (high-cer-
tainty evidence). In year 2, trial results weremore variable, with the
vaccine probably preventing between 45% and 69% of typhoid
cases (moderate-certainty evidence). These data included partici-
pants aged 2 to 55 years of age. The three-year cumulative efficacy
of the vaccinemay be around 55% (low-certainty evidence). These
data were taken from a single trial conducted in South Africa in
the 1980s in participants aged 5 to 15 years.
Compared with placebo, this vaccine probably did not increase
the incidence of fever (moderate-certainty evidence) or erythema
(low-certainty evidence); however, swelling (moderate-certainty
evidence) and pain at the injection site (moderate-certainty evi-
dence) were more common in the vaccine group.
See Summary of findings 2.
Vi-rEPA vaccine (two doses)
Administration of two doses of the Vi-rEPA vaccine probably pre-
vents between 50% and 96% of typhoid cases during the first two
years after vaccination (moderate-certainty evidence). These data
were taken from a single trial with children two to five years of age
conducted in Vietnam.
Compared with placebo, both the first and the second dose of this
vaccine increased the risk of fever (low-certainty evidence) and the
second dose increased the incidence of swelling at the injection
site (moderate-certainty evidence).
See Summary of findings 3.
Vi-TT vaccine (two doses)
We are uncertain of the efficacy of administering two doses of
Vi-TT (PedaTyph) in typhoid cases in children during the first
year after vaccination (very low-certainty evidence). These data
are taken from a single cluster-randomized trial in children aged
six months to 12 years conducted in India.
See Summary of findings 4.
WIth all vaccines, there were no reported serious adverse effects
in RCTs.
Overall completeness and applicability of
evidence
In the absence of trials directly comparing different types of ty-
phoid vaccines, we provide an indirect means of comparing the
efficacy of different vaccines. The cumulative efficacy at 2.5 to 3
years for the Ty21a vaccine (three doses) and the Vi polysaccharide
vaccine was 50% (95% CI 35% to 61%) and 55% (95% CI 30%
to 70%), respectively. Both of these vaccines are widely used but
are not immunogenic in children under two years old, which is a
limitation. A recent systematic review into burden of enteric fever
in children found contradictory evidence on the prevalence of ty-
phoid fever in children under the age of five, with a suspected hid-
den burden, which may be multi-factorial but includes diagnostic
difficulties in this age group (Britto 2017). The newer typhoid
conjugate vaccines address this gap, as they are suitable to use in
children under two years of age. The cumulative efficacy of the Vi-
rEPA vaccine at 3.8 years was higher (89%, 95%CI 76% to 97%),
but this vaccine is unlicensed and has not been used commercially.
Adverse events were mild in nature and, for the most part, were
not significantly different between vaccine and placebo groups.
There is information on efficacy in Asia for each of the vaccines.
There is limited data on efficacy of typhoid fever vaccination in
Africa, with one trial in Egypt for Ty21a, Wahdan 1980a EGY,
and one ViPs trial in South Africa, Klugman 1987 ZAF. There is
no information on efficacy of typhoid vaccination in sub-Saharan
Africa. There is evidence on efficacy for Ty21a in South America
(Levine 1987i CHL), but not for any of the other vaccines.
The newer typhoid conjugate vaccines Vi-TT (PedaTyph andTyp-
bar-TCV) show promise in immunogenicity studies but as of yet
efficacy data are only available for PedaTyph (two doses intramus-
cularly; Mitra 2016 IND). In October 2017, theWHO’s strategic
advisory group of experts (SAGE) recommended Typbar-TCV (1
dose intramuscularly; Mohan 2015) for children over six months
in typhoid endemic countries (WHO SAGE 2017), and in 2018
the WHO recommended this vaccine as the preferred choice for
adults and children from six months to 44 years of age (WHO
2018a). In a human challenge setting Typbar-TCV demonstrated
similar levels of efficacy in healthy adults to ViPS (Jin 2017), with
higher rates of seroconversion and higher antibody GMTs in the
conjugate vaccine group. At the time of writing, there were no
26Vaccines for preventing typhoid fever (Review)
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efficacy data on Typbar-TCV from field trials. Although promis-
ing, it is important to remember that human challenge studies are
inherently small. In addition, the bacterial load and the timing
of vaccination in relation to the challenge are highly controlled.
These studies cannot replace large-scale real-life RCTs as sole evi-
dence for approval of new vaccines but could be incorporated into
a more efficient approval process. An RCT assessed Typbar-TCV
versus ViPS for immunogenicity and safety in people aged 2 to
45 years old (Mohan 2015). Infants and children aged 6 to 23
months were observed in a non-controlled parallel trial. As there
was no placebo control group, the trial could not assess adverse
events from Typbar-TCV, but these were reported as similar with
TCV andViPs, fever being themost common, with a single serious
adverse event deemed unrelated to the vaccine. In an observational
group of children under two years in the same study, authors again
described adverse events as uncommon, with fever being the most
usual (Mohan 2015).
From the evidence available we cannot comment on vaccine herd
protection. As typhoid fever is spread faeco-orally through con-
taminated food and water, it is plausible that if endemic popula-
tions began to routinely use the vaccines, intensity of transmission
would be reduced due to a subsection of the population who were
protected against infection (Clemens 2011). However, we did not
find any studies describing the effect of vaccination on disease
burden in the rest of the community.
Quality of the evidence
We assessed the certainty of evidence provided by the randomized
studies using the GRADE approach, presenting our assessments
in Summary of findings for the main comparison, Summary of
findings 2, Summary of findings 3, and Summary of findings 4.
For the most widely used vaccines, oral Ty21a and ViPS, the evi-
dence of benefit is of moderate certainty. A main limitation for us
with Ty21a was the lack of cluster adjustment in trials using this
method. For our meta-analysis we estimated the effect of cluster-
ing, extrapolating from aViPs trial where clustering was taken into
account. For this reason we downgraded certainty to moderate.
Although there is moderate unexplained heterogeneity in the 2.5
to 3 year cumulative efficacy of Ty21a, the CIs fall within a clin-
ically important threshold, meaning the heterogeneity is unlikely
be clinically significant.
For ViPs the certainty of evidence for efficacy in year 1 was high,
but we downgraded it to moderate in the second year due to
unexplained heterogeneity. Efficacy in year 3 and the 2.5-year
cumulative efficacy was low, but only one trial assessed longer
follow-up in South Africa in children aged 5 to 15. There was also
imprecision as CIs were wide for both of these results.
The certainty of evidence for Vi-rEPA was moderate, as there was
a single trial, in one location (Vietnam) and only in children aged
two to five.
Certainty of evidence for the new Vi-TT vaccine is too limited
to clearly make a recommendation for its adoption. The certainty
of evidence for Vi-TT (PedaTyph) is very low. There was lack of
adjustment for cluster-randomization and a risk of bias (funding
by vaccine manufacturer, differing socioeconomic status between
vaccine and control group, and selective outcome reporting). As
the efficacy data is limited to one trial in children aged six months
to 12 years in one location in India, we also downgraded the
certainty of evidence for indirectness. The longer-term protection
for PedaTyph is still unknown, as only one-year follow-up data are
available.
There were no serious adverse events reported for any of the vac-
cines, so we could not assess certainty of evidence.
Potential biases in the review process
We estimated an ICC for unadjusted cluster-randomized trials
that might not be precise. We did not conduct sensitivity analyses
for the ICC, but we took a conservative approach and believe that
the estimates are reasonable.
Diagnosis of typhoid fever remains a challenge, which may have
affected the trial results for all of the vaccines. Our analysis for
vaccine efficacy relies on blood-culture positive typhoid fever; ty-
phoid fever cases that are blood culture negative were missed. In
one study the sensitivity of blood cultures compared to bone mar-
row cultures was only 66% (Mogasale 2014). However, all of the
trials that we included used positive blood culture for diagnosis
of typhoid fever, and we did not exclude any trials on this basis
of the efficacy outcome definition alone. Thus, we have presented
the evidence as completely as possible.
None of the vaccines identified protect against S. Paratyphi A, the
other ‘typhoidal’ serovar of Salmonella, and most vaccine trials did
not include outcomes for incidence of paratyphoid fever. Thus
results reflect efficacy against typhoid fever caused byS.Typhi alone
anddonot reflect the overall efficacy against the disease in locations
where S. ParatyphiA causes a significant number of cases.
We excluded human challenge studies as the bacterial inoculum
in challenge trials is much higher and the timing of infection rel-
ative to vaccination is highly controlled compared to the real life
situation, meaning the effect in real life is more difficult to ex-
trapolate.This could have introduced bias against this vaccine be-
cause we had fewer data available for some of the newer vaccines,
as human challenge studies provide results in a more time- and
cost-efficient manner compared to large scale implementation in
RCTs. We are examining the methodological aspects of this ap-
proach of evaluating vaccines and how best to assess and present
human challenge studies.
Agreements and disagreements with other
studies or reviews
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No other systematic reviews were identified since the last publica-
tion of this review in 2014.
WHO recommends ViPS in people over two years old and oral
Ty21a enteric capsules in people over six in areas with endemic
typhoid fever and for outbreak control. This review provides
evidence in support of this recommendation. The WHO rec-
ommends Vi-TT Typbar-TCV for infants and children over six
months old in typhoid endemic with catch-up vaccination where
feasible (WHO 2018a). This review does not provide evidence for
this recommendation, but it is likely that updates will when the
ongoing studies investigating Vi-TT Tybar-TCV are completed
(ISRCTN11643110; ISRCTN43385161; NCT03299426).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the available evidence from natural exposure, the cur-
rently licensed Ty21a and Vi polysaccharide vaccines are effica-
cious for preventing typhoid fever in children aged two years or
older and in young adults living in typhoid-endemic regions. Fac-
tors such as costs, availability and convenience of administration
may determine which vaccine is chosen for use.
We are uncertain of the effects of Vi-TT on typhoid fever, and
further data are needed to assess PedaTyph and Typbar-TCV ef-
ficacy in adults and children evaluated through natural exposure.
The recent approval of conjugate typhoid vaccine Typbar-TCV for
use in endemic countries by the WHO and SAGE; together with
the formation of the Typhoid Vaccine Acceleration Consortium
(TyVAC); results of some seroefficacy studies (Voysey 2018); and
the pending results of Typbar-TCV RCTs currently being con-
ducted inMalawi (NCT03299426), Nepal (ISRCTN43385161),
and Bangladesh (ISRCTN11643110), will help establish the firm
knowledge base required for the introduction of typhoid conju-
gate vaccines to endemic countries (Meiring 2017).
Implications for research
An effective typhoid vaccine is still needed for children under two
years of age. The new Vi-TT vaccines are promising; however,
at present there was only one trial available, which we judged to
have very low certainty-evidence. Further efficacy data are pend-
ing and are likely to change this certainty when available. Neither
the Vi polysaccharide vaccine nor the Ty21a vaccine is licensed
for children younger than two years of age. Future trials should
be sufficiently powered to present results stratified by age group.
This would mean that vaccine efficacy in different groups could
be analysed and would ensure that vaccine delivery can be tar-
geted appropriately (for example, via a school-based programme
or through the expanded programme of immunization (EPI)).
None of the included trials compared different types of vaccines
used to prevent typhoid fever. Such future comparisons may be
helpful in allowing direct conclusions regarding the relative effi-
cacy of the vaccines, although such evidence would not necessarily
promote the introduction of vaccines against typhoid fever to new
settings and would require substantial resources.
Future trials should conduct analyses suited to their design; cluster-
randomization should be accounted for in sample size calculations
and in analyses of results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Acharya 1987 NPL
Methods Design: individual-RCT
Active surveillance for efficacy (health workers visited vaccinees every 2 days; in case of
a fever lasting longer than 3 days, a blood sample was taken) and adverse events (health
workers examined vaccinees on days 1 to 3 postvaccination)
Participants Number: 6907
Inclusion criteria: age 5 to 44 years
Exclusion criteria: children age < 2 years; fever or acute illness; pregnancy
Interventions 1. Capsular polysaccharide of S. Typhi, Vi: 25 µg Vi in 0.5 mL; 3457 participants
2. Pneumococcal vaccine: 25 µg; 3450 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse events
Notes Location: 5 villages near Kathmandu, Nepal
Socioeconomic description: rural, low income
Setting: home
Date: 1986 to 1988
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized, random arrangement of sy-
ringes in packages of 10. Insufficient infor-
mation about the sequence generation pro-
cess provided to permit judgement
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of randomized assigned partici-
pants in analysis: 100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
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Acharya 1987 NPL (Continued)
Other bias Low risk None
Black 1990i CHL
Methods Design: cluster-RCT (classroom)
Intermediate surveillance for efficacy: enteric fever and isolation of S. Typhi from blood
or bone marrow in clinics and local hospital during the study (5-year follow-up)
Participants Number: 54,925 participants
Number of classrooms: 3655
Inclusion criteria: age 5 to 22 years
Exclusion criteria: no details
Interventions 1. Lyophilized attenuated S. Typhi strain Ty21a: enteric-coated capsule containing
2-5 × 109 viable Ty21a; 27,620 participants
2. Placebo: in enteric-coated capsule; 27,305 participants
Route and schedule: oral; 2 doses, 1 week apart
Concomitant medication: not specified
Outcomes Typhoid fever cases (S. Typhi bacteraemia or in bone marrow)
Notes Location: northern area of Santiago, Chile
Socioeconomic description: no details
Setting: school
Date: 1982 to 1987
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Low risk Allocation concealment: central (WHO).
Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of 91,954 participating children, 82,543
received all assigned doses. No reason for
missing data provided
Selective reporting (reporting bias) Low risk All expected outcomes reported on
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Black 1990i CHL (Continued)
Other bias Unclear risk Unclear whether data were adjusted for
clustering
Black 1990ii CHL
Methods
Participants
Interventions 1. Lyophilized attenuated S. Typhi strain Ty21a: enteric-coated capsule containing
2-5 × 109 viable Ty21a; 27,618 participants
2. Placebo: in enteric-coated capsule; 27,305 participants
Route and schedule: oral; 1 dose (2nd dose contained placebo in all participants)
Concomitant medication: not specified
Outcomes
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
Cryz 1993 THA
Methods Design: individual-RCT
Participants Number: 634
Inclusion criteria: children 2 to 6 years old with no history of typhoid fever
Exclusion criteria: no details
Interventions 1. Ty21a liquid formulation
2. Placebo
Route and schedule: oral solution; 3 doses
Outcomes 1. Adverse events
2. Immunogenicity
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Cryz 1993 THA (Continued)
Notes Location: Thailand
Socioeconomic description: no details
Date: no details
No demographic details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the allocation sequence: unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants per study arm not specified
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judgement
Other bias Low risk None
Keitel 1994 USA
Methods Design: individually based RCT
Active surveillance for adverse events: local and systemic symptoms before and at 24 and
48 hours after inoculation; fever and symptoms at 6 to 9 hours, days 1, 2, 7, 14 and 28
after inoculation
Participants Number: 323
Inclusion criteria: age 8 to 40 years; healthy; no previous typhoid vaccination
Exclusion criteria: no details
Interventions 1. Capsular polysaccharide of S. Typhi, Vi vaccine (freeze-dried preparation and
liquid preparation): 25 µg Vi in 0.5 mL; 237 participants
2. Placebo: 86 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Adverse events
2. Immunogenicity
Notes Location: Houston, Texas, USA
Socioeconomic description: urban, high income
Setting: clinic
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Keitel 1994 USA (Continued)
Date: no information
No demographic information
Results presented jointly for 3 separate trials
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Allocation concealment: unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk None
Khan 2012 PAK
Methods Design: cluster-RCT (geographic clusters)
Intermediate surveillance for efficacy: participants were identified through 3 study health
centres during study period (2 years)
Surveillance for adverse events: all participants were visited 30 minutes after vaccination;
a subgroup of 240 participants were visited 3 days after vaccination, and an adverse event
form was completed
Participants 51,965 participants
120 geographic clusters using the geographic information system (GIS) imagery (60
clusters in each study arm)
Inclusion criteria: children between the ages of 2 and 16 years
Exclusion criteria: married female children older than 12 years of age were not included
to avoid inadvertent immunization of pregnant women. Recent history of fever
Interventions 1. Single-dose capsular polysaccharide of S. Typhi, Vi vaccine (dose 25 mcg)
2. Hepatitis A vaccine (dose 720 IU)
Route and schedule: single intramuscular injection, Vi vaccine or hepatitis A vaccine
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Indirect protection from typhoid fever
3. Adverse events
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Khan 2012 PAK (Continued)
Notes Location: Karachi, Pakistan
Socioeconomic description: low-socioeconomic urban squatter settlements
Date: 2002 and 2007
Setting: vaccination centres and health centres
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A table of random numbers was used
Allocation concealment (selection bias) Low risk Vaccine identified by code, code assign-
ment held centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and investigators blinded - vac-
cines identified only by code. One vaccine
administered per cluster
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reason for missing data given (migration,
dying from other causes) and balanced
across groups
Selective reporting (reporting bias) Low risk Study protocol not available but published
study reports on both primary and sec-
ondary outcome
Other bias Low risk No recruitment bias, no baseline imbal-
ance, no loss of clusters, analysis adjusted
for clustering using generalized estimating
equation
Klugman 1987 ZAF
Methods Design: individually based RCT
Active surveillance for efficacy: blood cultures if febrile with no obvious clinical cause
Participants Number: 11,384
Inclusion criteria: 5 to 15 years
Exclusion criteria: no details
Interventions 1. Capsular polysaccharide of S. Typhi, Vi vaccine: 25 µg Vi; 5692 participants
2. Meningococcal vaccine: 25 µg Vi; 5692 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
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Klugman 1987 ZAF (Continued)
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Immunogenicity
Notes Location: eastern Transvaal area of South Africa
Socioeconomic description: no details
Setting: school
Date: 1985 to 1988
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization process unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance. Code held by independent
observers
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Vaccines identical in ap-
pearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nomissing outcome data. Inclusion of ran-
domized assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Levine 1986i CHL
Methods Design: individually based RCT
Active surveillance for adverse events: no further details
Participants Number: 539
Inclusion criteria: adults, no details
Exclusion criteria: no details
Interventions 1. Enteric-coated capsules S. Typhi Ty21a vaccine: 172 participants
2. Placebo: 367 participants
Route and schedule: oral capsules; 3 doses
Concomitant medication: not specified
Outcomes Adverse events
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Levine 1986i CHL (Continued)
Notes Location: Chile
Socioeconomic description: no details
Setting: no details
Date: no details
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Allocation concealment: unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Blinding: double-blind (no details)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: unclear
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Levine 1986ii CHL
Methods See Levine 1986i CHL (Levine 1986ii CHL is a different arm of the same trial with
separate placebo group)
Participants Number: 337
Inclusion criteria: children, no details
Exclusion criteria: no details
Interventions 1. S. Typhi Ty21a vaccine in milk with NaHCO3S: 172 participants
2. Placebo: 172 participants
Route and schedule: oral capsules; 3 doses
Concomitant medication: not specified
Outcomes Details as for Levine 1986i CHL
Notes Details as for Levine 1986i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
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Levine 1986ii CHL (Continued)
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1986i CHL
Allocation concealment (selection bias) Unclear risk Details as for Levine 1986i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1986i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1986i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1986i CHL
Other bias Low risk Details as for Levine 1986i CHL
Levine 1987i CHL
Methods Design: cluster-RCT (classroom)
Intermediate surveillance for efficacy: enteric fever and isolation of S. Typhi from blood,
bone marrow or bile-stained duodenal fluid in the hospital or in clinics during the trial
(3 years)
Participants Number: 27,074
Number of classrooms: 4312
Inclusion criteria: age 6 to 21 years; parental consent; no further details
Exclusion criteria: no details
Interventions 1. Enteric capsules of S. Typhi, Ty21a vaccine: 21,598 participants
2. Placebo: 5476 participants (placebo group divided into 4 equal groups for the
comparison)
Route and schedule: oral capsules; 3 doses given 21 days apart
Concomitant medication: not specified
Outcomes Typhoid fever cases (S. Typhi bacteraemia, in bone marrow or in duodenal fluid)
Notes Location: Chile socioeconomic description: no details
Setting: school
Date: 1983 to 1986
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
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Levine 1987i CHL (Continued)
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: 78% (109,594/141,127)
of enrolled children received 3 doses and
included in results. No reason for missing
data given
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Analysis not adjusted for clustering
Levine 1987ii CHL
Methods See Levine 1987i CHL (Levine 1987ii CHL is a different arm of the same trial)
Details as for Levine 1987i CHL, except blinding: placebo given in a similar regimen,
but not mentioned if identical to gelatin or enteric capsules
Participants Details as for Levine 1987i CHL, except number: 27,647
Interventions 1. Enteric capsules of S. Typhi, Ty21a vaccine: 22,170 participants
2. Placebo: 5477 participants (placebo group divided into 4 equal groups for the
comparison)
Route and schedule: oral capsules; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
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Levine 1987ii CHL (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
Levine 1987iii CHL
Methods See Levine 1987i CHL (Levine 1987iii CHL is a different arm of the same trial)
Participants Details as for Levine 1987i CHL, except number: 27,017
Interventions Details as for Levine 1987i CHL, except:
1. Gelatin capsules of S. Typhi, Ty21a vaccine: 21,541
2. Placebo: 5476 (placebo group divided into 4 equal groups for the comparison)
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
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Levine 1987iv CHL
Methods See Levine 1987i CHL (Levine 1987iv CHL is a different arm of the same trial)
Details as for Levine 1987i CHL, except blinding: placebo given in a similar regimen,
but not mentioned whether identical to gelatin or enteric capsules
Participants Details as for Levine 1987i CHL, except number: 27,856
Interventions 1. Gelatin capsules of S. Typhi, Ty21a vaccine: 22,379 participants
2. Placebo: 5477 participants (placebo group divided into 4 equal groups for the
comparison)
Route and schedule: oral capsules; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes Details as for Levine 1987i CHL
Notes Details as for Levine 1987i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1987i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1987i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1987i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1987i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1987i CHL
Other bias Unclear risk Details as for Levine 1987i CHL
Levine 1990i CHL
Methods Design: cluster-RCT (classroom)
Intermediate surveillance for efficacy: enteric fever and isolation of S. Typhi from blood,
bone marrow or bile-stained duodenal fluid in the hospital or in clinics during the study
(5 years)
Participants Number: 42,073
Number of classes: 5423
Inclusion criteria: 5 to 19 years old; parental consent; no further details
Exclusion criteria: no details
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Levine 1990i CHL (Continued)
Interventions 1. Liquid formulation of S. Typhi, Ty21a vaccine: 36,623 participants
2. Placebo: 5450 participants
Route and schedule: oral solution; 3 doses given 2 days apart
Concomitant medication: not specified
Outcomes Typhoid fever cases (S. Typhi bacteraemia, in bone marrow or in duodenal fluid)
Notes Location: Chile
Socioeconomic description: no details
Setting: school
Date: 1986 to 1991
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Low risk Sequentially numbered vaccines of identi-
cal appearance. Code kept at WHO
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical packets and cap-
sules
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Inclusion of randomly assigned partici-
pants in analysis: 85% (81,621/95,910
children who received at least 1 dose) re-
ceived all 3 doses and included in results.
No reason for missing data given
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Unclear risk Analysis not adjusted for clustering; how-
ever, authors state, “analysis of cases by class
after three years of follow-up showed no
clustering”
Levine 1990ii CHL
Methods See Levine 1990i CHL (Levine 1990ii CHL is a different arm of the same trial)
Details as for Levine 1990i CHL, except intermediate surveillance for efficacy for 3 years
Participants Details as for Levine 1990i CHL, except number: 39,548
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Levine 1990ii CHL (Continued)
Interventions Details as for Levine 1990i CHL, except:
1. Enteric capsules of S. Typhi, Ty21a vaccine: 34,696 participants
2. Placebo: 4852 participants
Outcomes Details as for Levine 1990i CHL
Notes Details as for Levine 1990i CHL
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Details as for Levine 1990i CHL
Allocation concealment (selection bias) Low risk Details as for Levine 1990i CHL
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Levine 1990i CHL
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Details as for Levine 1990i CHL
Selective reporting (reporting bias) Low risk Details as for Levine 1990i CHL
Other bias Unclear risk Details as for Levine 1990i CHL
Lin 2001 VNM
Methods Design: individually based RCT
Active surveillance for efficacy and adverse events: weekly history; temperature; blood
cultures and serology if febrile during the trial (27 months); review of bacteriological
records in the provincial hospital
Passive surveillance: 19 additional months
Participants Number: 12,008
Inclusion criteria: age 2 to 5 years; no further details
Exclusion criteria: illnesses that required ongoing medical care; fever > 37.5°C at first
injection
Interventions 1. Vi-rEPA vaccine; capsular polysaccharide of S. Typhi, Vi, bound to a nontoxic
recombinant protein that is antigenically identical to Pseudomonas aeruginosa exotoxin
A; 22 µg Vi in 0.5 mL; 5991 participants
2. Placebo: 6017 participants
Route and schedule: intramuscular injection; 2 doses, 6 weeks apart
Concomitant medication: not specified
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Lin 2001 VNM (Continued)
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse events
3. Immunogenicity
Subgroups for gender, age and study year
Notes Location: Dong Thap Province, Mekong Delta, Vietnam
Socioeconomic description: rural; low income
Setting: home
Date: 1998 to 2000
Sex, age at vaccination, household composition and size and interval between the 2
injections similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Identical looking vaccine and placebo were
randomly numbered 0 to 9 and packaged
in packets of 10; however, unclear how ran-
domization sequence generated
Allocation concealment (selection bias) Low risk Code identifying identical-looking vaccine
and placebo was kept at the central phar-
macy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Vaccine and placebo vials
indistinguishable
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Low risk None
Mitra 2016 IND
Methods Design: open label, cluster-RCT (school)
12 months active follow-up: weekly telephone follow-up, monthly social worker follow-
up in school, school absenteeism record and subject diary kept by parent (collected after
12 months)
Participants Number: 1765
Inclusion criteria: children 6 months to 12 years old. 12 schools in 2 municipal wards
in Kolkata, India. Voluntary written informed consent from parent/guardian
Siblings of school children aged 6 months to 3 years were also invited
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Mitra 2016 IND (Continued)
Exclusion criteria: fever > 38.5°C at time of enrolment or history of undiagnosed fever/
infection of more than 3 days duration within 1 month prior to vaccination, established
or clinically suspected immunosuppressive or immune compromised disorder/state (con-
genital or acquired drug induced, neoplastic, TB etc), anyone who had a typhoid vacci-
nation in the last 3 years and with a known allergy to any of the components in PedaTyph
Interventions 1. PedaTyph (test group): containing 5micrograms of Vi polysaccharide of S. Typhi
conjugated to 5 µg of tetanus toxoid (Vi-TT): 905 participants
2. Normal vaccination course (control): 860 participants
Route and administration: 2 doses of PedaTyph vaccine 0.5 mL administered intramus-
cularly in the upper arm with a 6 week interval between doses
Concomitant medication: not specified
Outcomes 1. Microbiologically proven (BACTEC positive) Typhoid fever
2. Immunogenicity
3. Adverse effects at 30 minutes, 1 month and clinical events up to 12 months
(observational as no placebo comparison)
Notes Location: Kolkata, India
Socioeconomic description: low income, urban
Setting: school
Date: no details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistician used graph pad software to gen-
erate random numbers to assign clusters to
vaccine and control group
Allocation concealment (selection bias) Low risk Allocationby a statisticianwhowas blinded
as to clusters
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label - no placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 lost to follow-up in test groupdue tomov-
ing out of area. Although 140 patients in
the test group did not get the second dose
of the vaccine they were all followed up
Selective reporting (reporting bias) High risk Paratyphoid cases were not reported (as
was intended in the protocol registered
prospectively)
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Mitra 2016 IND (Continued)
Other bias High risk According to prospectively published pro-
tocol, funding was by the company who
manufacturers the Peda Typh vaccine (no
mention of this in the published trial)
The intervention and the control group
were very different in terms of socioeco-
nomic status, with lower status in the con-
trol group
The trial results were unadjusted for cluster
randomization.
Olanratmanee 1992 THA
Methods Design: individually based RCT
Active surveillance for adverse events: 1.5 hours of observation and parental reporting
via adverse event report sheet
Participants Number: 170
Inclusion criteria: age 4 to 6 years; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. Typhi, TY21a: 88 participants
2. Placebo: 82 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes 1. Adverse events
2. Immunogenicity
Notes Location: Thailand
Socioeconomic description: no details
Setting: clinic
Date: no details
No demographic information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: not
mentioned
Allocation concealment (selection bias) Unclear risk Allocation concealment: no information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical vaccine and
placebo packages
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Olanratmanee 1992 THA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Simanjuntak 1991i IDN
Methods Design: individually based RCT
Intermediate surveillance for efficacy: isolation of S. Typhi from blood during trial (2.5
years)
Surveillance for adverse events: questionnaires collected from 588 individuals
Participants Number: 10,212
Inclusion criteria: age 3 to 44 years; no further details
Exclusion criteria: pregnant women; febrile illness
Interventions 1. Liquid formulation of S. Typhi, Ty21a: 5066 participants
2. Placebo: 5146 participants
Route and schedule: oral solution; 3 doses, 1 week apart
Concomitant medication: not specified
Note Simanjuntak 1991ii IDN is 2 different arms of the same trial (see below for further
details). Simanjuntak 1991i IDN and Simanjuntak 1991ii IDN had different placebo
groups
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse events
Subgroups for age and study year
Notes Location: Plaju and Sungai Gerong, Sumatra, Indonesia
Socioeconomic description: no details
Setting: clinic
Date: 1986 to 1989
Sex, age at vaccination, residence in a compound, history of typhoid vaccination and
level of education similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: com-
puter-generated table of random numbers
Allocation concealment (selection bias) Low risk Identical vaccine and placebo
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Simanjuntak 1991i IDN (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical vaccine and
placebo
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% of participants (20,543/22,001) re-
ceived 3doses and included in results.Miss-
ing outcome data balanced across interven-
tion and control groups
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Low risk None
Simanjuntak 1991ii IDN
Methods See Simanjuntak 1991i IDN (Simanjuntak 1991ii IDN is a different arm of the same
trial)
Details as for Levine 1990i CHL, except surveillance for adverse events: questionnaires
collected from 602 individuals
Participants Details as for Simanjuntak 1991i IDN, except number: 10,331
Interventions 1. Enteric capsules of S. Typhi, Ty21a: 5209 participants
2. Placebo: 5122 participants
Route and schedule: oral capsules; 3 doses, 1 week apart
Concomitant medication: not specified
Note Simanjuntak 1991i IDN is two different arms of the same trial (see above for
further details). Simanjuntak 1991i IDN and Simanjuntak 1991ii IDN had different
placebo groups
Outcomes Details as for Simanjuntak 1991i IDN
Notes Details as for Simanjuntak 1991i IDN
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Details as for Simanjuntak 1991i IDN
Allocation concealment (selection bias) Low risk Details as for Simanjuntak 1991i IDN
Blinding (performance bias and detection
bias)
All outcomes
Low risk Details as for Simanjuntak 1991i IDN
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Simanjuntak 1991ii IDN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Details as for Simanjuntak 1991i IDN
Selective reporting (reporting bias) Low risk Details as for Simanjuntak 1991i IDN
Other bias Low risk Details as for Simanjuntak 1991i IDN
Sur 2009 IND
Methods Design: cluster-RCT (geographic clusters)
Active surveillance for efficacy: 5 study clinics were established to conduct surveillance
for febrile illnesses and to refer participants with severe disease for hospital care during
study period (2 years)
Surveillance period adverse events: all participants 30minutes after vaccination, subgroup
of 320 participants for 3 consecutive days, passive surveillance for adverse events for 1
month at all study clinics and hospitals
Participants 37,673 participants
80 contiguous geographic clusters (40 clusters in each study group)
Inclusion criteria: 24 months of age and older, no reported fever or had an axillary
temperature not greater than 37.5°C at time of administration
Exclusion criteria: not stated
Interventions 1. Single-dose capsular polysaccharide of S. Typhi, Vi vaccine (dose 25 mcg)
2. Inactivated hepatitis A vaccine (dose 720 IU for children 2 to 18, 1440 IU for
adults)
Route and schedule: single intramuscular injection, Vi vaccine or inactivated hepatitis
A vaccine
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Indirect protection from typhoid fever
3. Adverse events
Notes Location: Kolkata, India
Socioeconomic description: slum-dwelling residents
The clusters were stratified according to ward and the number of residents who were 18
years of age or younger (< 200 versus ≥ 200 people) and the number of residents who
were older than 18 years (< 500 versus ≥ 500 people), resulting in 8 strata
Date: November 2004 to December 2006
Setting: vaccination centres set up for each cluster and health clinics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Used a table of random numbers to assign
half the 80 clusters to each vaccine”
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Sur 2009 IND (Continued)
Allocation concealment (selection bias) Low risk “The vaccines were labelled only with code
letters.”However, 2 vaccineswere not pack-
aged in an identical fashion. Attempts to
minimize this bias unlikely to have affected
the findings of the trial
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants and study personnel blind.
Not stated whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing data given (migra-
tion, dying fromother causes) andbalanced
across groups
Selective reporting (reporting bias) Low risk Study protocol not available but published
study reports on both primary and sec-
ondary outcomes
Other bias Low risk No recruitment bias, no baseline imbal-
ance, no loss of clusters, analysis adjusted
for clustering using generalized estimating
equation
Wahdan 1980a EGY
Methods Design: cluster-RCT (classroom)
Intermediate surveillance for efficacy: isolation of S. Typhi from blood in the hospital
during the study (3 years)
Surveillance for adverse events: no details
Participants Number: 32,388
Inclusion criteria: age 6 to 7 years; no further details
Exclusion criteria: no details
Interventions 1. Liquid formulation of S. Typhi, Ty21a: 16,486 participants
2. Placebo: 15,902 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse events
Notes Location: Alexandria, Egypt
Socioeconomic description: no details
Setting: school
Date: 1978 to 1981
No demographic information
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Wahdan 1980a EGY (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Vaccine and placebo identical. Allocation
concealment unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Vaccine and placebo identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Unclear risk Analysis not adjustment for clustering
Wahdan 1980b EGY
Methods Design: cluster-RCT (classroom)
Surveillance for adverse events: no details
Participants Number: 884
Inclusion criteria: age 6 to 7 years; no further details
Exclusion criteria: no details
This trial was a pilot study done prior to Wahdan 1980a EGY (see above) to assess
tolerability of the vaccines. Results were presented as part of the trial data for Wahdan
1980a EGY.
Interventions 1. Liquid formulation of S. Typhi, Ty21a: 413 participants
2. Placebo: 471 participants
Route and schedule: oral solution; 3 doses, alternate days
Concomitant medication: not specified
Outcomes Adverse events
Notes Location: Alexandria, Egypt
Socioeconomic description: no details
Setting: school
Date: 1978
No demographic information
Risk of bias
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Wahdan 1980b EGY (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence: unclear
Allocation concealment (selection bias) Unclear risk Vaccine and placebo identical. Allocation
concealment unclear
Blinding (performance bias and detection
bias)
All outcomes
Low risk Vaccine and placebo identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Unclear risk All expected outcomes reported on
Other bias Unclear risk Analysis not adjusted for clustering
Wang 1997 CHN
Methods Design: individually based RCT
Passive surveillance for efficacy: signs and symptoms of typhoid fever; blood cultures and
serum Widal’s test (1 year)
Participants Number: 81,506
Inclusion criteria: age 5 to 55 years; healthy
Exclusion criteria: history of liver, kidney or heart disease; hypertension; acute infection;
psychiatric disease; allergic history; prior typhoid infection; pregnancy; prior typhoid
vaccination in the last 2 years
Interventions 1. Capsular polysaccharide of S. Typhi, Vi vaccine: 30 µg Vi: 41,118 participants
2. Meningococcal vaccine: 40,388 participants
Route and schedule: intramuscular injection; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse reactions
Subgroups for age and gender
Notes Location: Baoying County, Jiangsu Province, China
Socioeconomic description: no details
Setting: no details
Date: 1994 to 1995
No demographic information
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Wang 1997 CHN (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: com-
puter-generated random numbers
Allocation concealment (selection bias) Low risk Allocation concealment: code concealed
from field workers and study population
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind. Identical vaccine and
placebo vials
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data. Inclusion of
randomly assigned participants in analysis:
100%
Selective reporting (reporting bias) Low risk All expected outcomes reported on
Other bias Low risk None
Yang 2001 CHN
Methods Design: individually based RCT
Passive surveillance for efficacy: clinical symptoms; positive blood cultures and serum
Widal’s test during trial (1.6 years)
Surveillance for adverse events: parental reporting of adverse effects in 3 schools
Participants Number: 131,271
Inclusion criteria: healthy children aged 3 to 19 years and adults aged < 51 years
Exclusion criteria: chronic disease; under medication; pregnancy
Interventions 1. Capsular polysaccharide of S. Typhi, Vi vaccine: 30 µg Vi; 65,287 participants
2. Placebo: 65,984 participants
Route and schedule: hypodermically; 1 dose
Concomitant medication: not specified
Outcomes 1. Typhoid fever cases (S. Typhi bacteraemia)
2. Adverse events
Subgroups for age, profession and sex
Notes Location: county of Quan, north-eastern part of Guangxi Zhuang
Autonomous Region, southern China
Socioeconomic description: no details
Setting: clinic
Date: 1995 to 1996
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Yang 2001 CHN (Continued)
Age, sex and profession similar in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of allocation sequence: unique
serial number to each participant; having
an even or an odd number determined al-
location to vaccine or placebo
Allocation concealment (selection bias) Low risk Allocation concealment: code concealed
from field workers and study population
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Zhou 2007 CHN
Methods Design: individually based RCT
Active surveillance for adverse events: all participants were observed for 2 hours at the
vaccination
site after administration of the study agent and were visited by trained clinicians on days
1, 2, 3 and 28
Participants Number: 667
Inclusion criteria: school children aged 9 to 14 who have previously received a primary
dose of Vi vaccine, no signs or symptoms consistent with an infection within the 2 weeks
before injection, no history of typhoid fever and axillary temperature of 37.5°C on the
day of the planned injection
Exclusion criteria: no previous primary dose of Vi vaccine, signs or symptoms of infection
within the 2 weeks before injection, history of typhoid fever or axillary temperature
higher than 37.5°C on day of planned injection
Interventions 1. Capsular polysaccharide of S. Typhi, Vi vaccine to previously vaccinated children
(revaccination), 334 participants
2. Placebo (normal saline), 333 participants
Route and schedule: intramuscular injection, one dose
Outcomes Adverse events
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Zhou 2007 CHN (Continued)
Notes Location: Suzhou, Jiangsu, China
Socioecomic description: no details
Setting: school
Date: 2002
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer generated random numbers”
Allocation concealment (selection bias) Unclear risk Insufficient information to permit judge-
ment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind - blinding of participants
and study personnel. Vaccine and placebo
identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All expected outcomes reported
Other bias Low risk None
Cluster-RCT: randomized controlled trial that randomly assigned clusters (for example, classrooms); ELISA: enzyme-linked im-
munosorbent assay; individually-based RCT: randomized controlled trial that randomly assigned individual participants; WHO:
World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ali 2011 No relevant outcome measures
Arya 1997 Letter; not an RCT
Ashcroft 1967 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Bhutta 2014 No efficacy data yet for Vi-CRM197 so according to protocol cannot include for side effects/safety only
Black 1983 No relevant outcome measures
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(Continued)
Blomke 2017 Additional info for Darton 2016 - human challenge study - already excluded
Bumann 2001 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of this vaccine
Cahn 2004 Study arms randomly assigned to receive different doses of same vaccine
Chuttani 1977 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Cordero-Yap 2001 Compared 2 Vi polysaccharide vaccines made by 2 different companies
Cryz 1995 No relevant control group
Cumberland 1992 Evaluated Vi vaccine versus inactivated whole-cell vaccine, which is no longer in use
Darton 2016 Human challenge study
Ferreccio 1989 RCT compared different doses of the Ty21a vaccine
Hejfec 1965 Two separate randomized trials, described together; none of the chemical subunit vaccines that were studied
are in use
Hejfec 1966 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1968 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1969 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hejfec 1976 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Hien 2010 Evaluated adverse events of new M01ZH09 vaccine, no efficacy trials of this vaccine
Hohmann 1996a No random allocation
Hohmann 1996b No random allocation
House 2011 Vi-CRM197 human challenge study. Published protocol and note on register that ended prematurely
Jin 2017 Vi-TT (Typbar-TCV) - human challenge study - excluded
Juel 2018 Additional information on Darton 2016 - excluded as human challenge study
Kantele 2013 No relevant outcome measures
Keddy 1999 No relevant outcome measures
Khan 2007 Non-randomized study
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Khoo 1995 Evaluated safety of Vi vaccine compared with meningococcal vaccine or combination
Kirkpatrick 2006 Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine
Lebacq 2001 Evaluated different brands of Vi vaccine
Levin 1975 No random allocation; compared Vi with inactivated whole-cell vaccine, which is no longer in use
Lyon 2010 Evaluated adverse events of new M01ZH09 vaccine; no efficacy trials of this vaccine
Meiring 2017 Review article - no new trials referenced
Mohan 2015 No efficacy data for Typbar TCV yet so excluded as per protocol as must have efficacy data available for
vaccine for adverse effects to be included in review
Murphy 1991 No random allocation to vaccine and placebo arms
Nisini 1993 No random allocation
Ochiai 2014 No efficacy or adverse effects/safety outcomes
Panchanathan 2001 Compared Vi vaccine with inactivated whole-cell vaccine, which is no longer in use
Polish committee 1966 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Sabitha 2004 Compared 2 brands of Vi vaccine
Tacket 1992 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
Tacket 1997 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
Tacket 2000 Evaluated experimental live-attenuated oral vaccine candidates; no efficacy trials of these vaccines
Tapa 1975 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Thiem 2006 No relevant outcome measures
Thiem 2011 Adverse event only trial and placebo not used for comparison (Hibb vaccine used as comparison)
van Damme 2011 Evaluated adverse events of new conjugate vaccine (Vi-CRM); no efficacy trials of this vaccine
Voysey 2018 Additional data for Mohan 2015 - Vi-TT (Typbar-TCV) - no efficacy data, immunological data
Wahdan 1975 Quasi-RCT evaluating the inactivated whole-cell vaccine, which is no longer in use
Wahid 2011 No relevant outcome measures
63Vaccines for preventing typhoid fever (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Yang 2005 No relevant outcome measures
Yang 2009 Safety only, evaluated different brands of same vaccine
Yug Ty Comm 1962 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Yug Ty Comm 1964 Evaluated the inactivated whole-cell vaccine, which is no longer in use
Zhou 2008 CHN Safety only; evaluated different brands of same vaccine
RCT: randomized controlled trial.
Characteristics of ongoing studies [ordered by study ID]
ISRCTN11643110
Trial name or title Assessing the impact of a Vi-polysaccharide conjugate vaccine in preventing typhoid infection among
Bangladeshi children - a phase IV trial
Methods Cluster-randomized controlled trial
Participants Consenting children/guardians within the age range (9 months to < 16 years) residing in the area of Mirpur,
Dhaka
Inclusion criteria:
1. Parent/guardian is willing and competent to provide informed consent. If the participant is 11 to < 16
years of age, informed assent will also be sought
2. Aged between 9 months (or eligible for measles vaccination according to local protocol) and <16 years
(that is, up to 15 years 364 days) at time of vaccination
3. Apparently healthy (no complaints of febrile illness) on the day of vaccination
4. Parent/guardian confirms that their child will be willing and be able to comply with study
requirements including follow-up contact, according to the schedule
5. Living within the study catchment area at the time of vaccination
Exclusion criteria:
1. Has knowingly received a typhoid or Japanese encephalitis vaccine in the last three years
2. Known allergy to any of the vaccine components
3. Medical or social reasons that will prevent the participant from conforming to the study requirements
as judged by a medical professional
4. Planning to move away from the catchment area within the next month
5. Pregnant at the time of vaccination, as confirmed by a urine test (urine pregnancy test will be done in
girls who are married)
Target number of participants: 43,350
150 Residential clusters of around 1250 people each are randomized in a 1:1 ratio to receive Vi-TCV or the
control vaccine (SA 14-14-2)
Interventions Intervention: Vi Typhoid conjugate vaccine (Vi-TCV), trade name: TyBar
Control: Japanese encephalitis vaccine: trade name: SA14-14-2, Japanese encephalitis vaccine, Live
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ISRCTN11643110 (Continued)
Outcomes Primary outcome: the efficacy and rate reduction of the Vi-TCV in preventing blood culture-confirmed
symptomatic infection caused by S. Typhi, measured through the incidence of blood culture confirmed
typhoid fever in vaccinees in intervention clusters compared to control clusters
Secondary outcomes: Vi-TCV safety, efficacy and rate reduction of typhoid fever in clusters, impact on fever
presentation, impact on clinical diagnosis typhoid fever, paratyphoid fever infection rates
Starting date 12 February 18
Contact information Prof Andrew Pollard,
Oxford Vaccine Group
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Churchill Hospital Old Road
Oxford
OX3 7LE
United Kingdom
Notes A pilot phase, prior to the main study, individually randomises 200 children, in an area separate from the
main trial site, in an age stratified manner to receive either Vi-TCV or the JE vaccine. Safety data is presented
to the local DSMB (LDSMB), IRB and to the Directorate General of Drug Administration (DGDA), the
National Regulatory Authority of Bangladesh prior to initiating the main cluster-randomized trial
Intention to publish date: 1 February 2021
Trial protocol available: www.isrctn.com/ISRCTN11643110
ISRCTN43385161
Trial name or title Assessing the impact of aVi-polysaccharide conjugate vaccine in preventing typhoid infection amongNepalese
children - a phase III trial
Methods Randomized controlled trial
Participants Inclusion criteria
1. Parent/legal guardian is willing and competent to provide informed consent. If the participant is 12
years of age or older, informed assent will also be sought
2. Aged between 9 months (or eligible for measles vaccination according to local protocol) and < 16 years
(that is, up to 15 years 364 days) at time of vaccination
3. In good health on the day of vaccination
4. Parent/legal guardian confirms that their child will be wiling and be able to comply with study
requirements including follow-up contact, according the trial schedule
5. Live within the study catchment area at the time of vaccination
Exclusion criteria
1. Parent/legal guardian is willing and competent to provide informed consent. If the participant is 12
years of age or older, informed assent will also be sought
2. Aged between 9 months (or eligible for measles vaccination according to local protocol) and < 16 years
(that is, up to 15 years 364 days) at time of vaccination
3. In good health on the day of vaccination
4. Parent/legal guardian confirms that their child will be wiling and be able to comply with study
requirements including follow-up contact, according the trial schedule
5. Live within the study catchment area at the time of vaccination
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ISRCTN43385161 (Continued)
Target number of participants: 20,000
Interventions Intervention: Vi Typhoid conjugate vaccine (Vi-TCV), trade name: TyBar, single dose
Control: meningococcal group A vaccine (MenA), trade name: MenAfriVac, single dose
Outcomes Primary outcome: efficacy and rate reduction of Vi-TCV in preventing blood culture confirmed S. Typhi
infection
Secondary outcomes: safety of Vi-TCV, impact on admission rates for febrile illness days spent in hospital
with febrile illness, incidence of clinically suspected typhoid fever, paratyphoid infection rates
Follow-up: 2 years
Starting date 1 November 2017
Contact information Prof Andrew Pollard
Oxford Vaccine Group
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
Churchill Hospital Old Road
Oxford
OX3 7LE
United Kingdom
Notes Intention to publish date: 1 August 2021
Trial protocol: www.isrctn.com/ISRCTN43385161
NCT03299426
Trial name or title A phase III randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine
(Vi-TCV) among children age 9 months through 12 years in Blantyre, Malawi
Methods Randomized controlled trial
(Participant, investigator, outcomes assessor blinded)
Participants Inclusion criteria
• Healthy male or female child between the ages of 9 months and 12 years/364 days at the time of study
vaccination
• A child whose parent or guardian resides primarily within the Ndirande or Zingwangwa study areas at
the time of study vaccinations and who intends to be present in the area for the duration of the trial
• A child whose parent or guardian has voluntarily given informed consent
Exclusion criteria
• History of documented hypersensitivity to any component of the vaccine
• Prior receipt of any typhoid vaccine in the past 3 years
• History of severe allergic reaction with generalized urticarial, angioedema, or anaphylaxis
• Any condition determined by the investigator to be likely to interfere with evaluation of the vaccine or
to be a significant potential health risk to the child or make it unlikely that the child would complete the
study
Target number of participants: 24,000
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NCT03299426 (Continued)
Interventions Intervention: Vi-typhoid conjugate vaccine (Vi-TCV); single 0.5-mL intramuscular injection
Control: meningococcal A conjugate vaccine (MCV-A); single intramuscular injection. Children 9-11months
will receive a 5 µg/0.5 mL dose. Children 12 months and older will receive a 10 µg/0.5 mL dose
Outcomes Primary outcome: efficacy of Vi-TCV (blood culture confirmed; follow-up until 36 months)
Secondary outcomes: safety of Vi-TCV (follow-up until 6 months); immunogenicity of Vi-TCV (28 days);
number of typhoid fever cases prevented by Vi-TCV (follow-up until 36 months)
Starting date January 2018
Contact information Principal Investigator: Kathleen Neuzil, Professor, University of Maryland
Provided contact details: Kenneth Simiyu Ksimiyu@som.umaryland.edu; Ian Woods
iwoods@som.umaryland.edu
Notes Estimated study completion date: January 2021
Trial protocol: clinicaltrials.gov/show/NCT03299426
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D A T A A N D A N A L Y S E S
Comparison 1. Ty21a vaccine (3 doses) versus control: efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever, year 1 4 76296 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.35, 0.86]
2 Incidence of typhoid fever, year 2 4 76296 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.29, 0.57]
3 Incidence of typhoid fever, year 3 4 76296 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.25, 0.76]
4 Cumulative incidence of typhoid
fever at 2.5 to 3 years
9 235239 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.39, 0.65]
Comparison 2. Ty21a vaccine: liquid formulation versus enteric capsules (3 doses)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cumulative incidence of typhoid
fever at 2.5 to 3 years
2 80127 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.23]
Comparison 3. Ty21a vaccine: enteric versus gelatin formulation; cumulative efficacy at 2.5 to 3 years
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 4. Ty21a vaccine versus control: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever 4 2066 Risk Ratio (M-H, Random, 95% CI) 1.84 [1.02, 3.31]
2 Vomiting 4 2066 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.43, 3.05]
3 Diarrhoea 4 2066 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.52, 1.24]
4 Nausea or abdominal pain 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Enteric capsules 2 1141 Risk Ratio (M-H, Random, 95% CI) 2.92 [1.53, 5.57]
4.2 Liquid formulation 1 588 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.90, 3.77]
4.3 In milk with sodium
bicarbonate
1 337 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.39, 1.13]
5 Headache 2 1190 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.76, 2.27]
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6 Rash 2 1190 Risk Ratio (M-H, Random, 95% CI) 2.94 [0.61, 14.12]
7 Any mild adverse event 3 1360 Risk Ratio (M-H, Random, 95% CI) 1.67 [1.03, 2.72]
Comparison 5. Vi polysaccharide vaccine (1 dose) versus control: efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever 6 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Year 1 3 99797 Risk Ratio (Random, 95% CI) 0.31 [0.26, 0.37]
1.2 Year 2 4 194969 Risk Ratio (Random, 95% CI) 0.41 [0.31, 0.55]
1.3 Year 3 1 11384 Risk Ratio (Random, 95% CI) 0.50 [0.32, 0.78]
2 Cumulative incidence of typhoid
fever at 2.5 to 3 years
1 11384 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.30, 0.70]
Comparison 6. Vi polysaccharide vaccine versus control: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever 4 133038 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.85, 1.14]
2 Erythema 3 132261 Risk Ratio (M-H, Random, 95% CI) 3.04 [0.45, 20.30]
3 Swelling at injection site 3 1767 Risk Ratio (M-H, Random, 95% CI) 6.06 [1.07, 34.22]
4 Pain at injection site 1 667 Risk Ratio (M-H, Random, 95% CI) 7.98 [3.69, 17.24]
5 Serious adverse events 4 133038 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Vi-rEPA (2 doses) versus control: efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Year 1 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.25]
1.2 Year 2 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.04, 0.44]
1.3 Cumulative 2 years 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.04, 0.22]
1.4 Cumulative 46 months 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.05, 0.23]
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Comparison 8. Vi-rEPA vaccine versus control: adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Fever after Vi-rEPA (dose1) 1 12008 Risk Ratio (M-H, Random, 95% CI) 2.54 [1.69, 3.82]
2 Fever after Vi-rEPA (dose 2) 1 11091 Risk Ratio (M-H, Random, 95% CI) 4.39 [2.85, 6.77]
3 Erythema after Vi-rEPA (dose 1) 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Erythema after Vi-rEPA (dose 2) 1 11091 Risk Ratio (M-H, Random, 95% CI) 2.01 [0.18, 22.21]
5 Swelling at injection site after
Vi-rEPA (dose 1)
1 12008 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Swelling at injection site after
Vi-rEPA (dose 2)
1 11091 Risk Ratio (M-H, Random, 95% CI) 20.15 [2.71, 150.08]
7 Serious adverse events 1 12008 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 9. Vi-TT vaccine Peda Typh (2 doses) versus control: efficacy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of typhoid fever, Year
1
1 1353 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.00, 1.01]
A D D I T I O N A L T A B L E S
Table 1. Cluster-randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results
Trial Year Preparation
(N doses)
ICCa Average
cluster size
Design
effect
Typhoid
episodes/
participants
in interven-
tion group
Typhoid
episodes/
participants
in in control
group
Risk ratio
(95% CI)
Levine
1987i CHL
1 Enteric cap-
sules (3)
0.0015 25 1.036 7/21,400 6/5286 0.29 (0.10 to
0.86)
2 1.036 8/21,400 5/5286 0.40 (0.13 to
1.21)
3 1.036 8/21,400 6/5286 0.33 (0.11 to
0.95)
Wahdan
1980a EGY
1 Liquid for-
mulation (3)
0.0015 37 1.054 0/13,980 7/15,087 0.07 (0.00 to
1.26)
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Table 1. Cluster-randomized trials: efficacy of oral Ty21a (3 doses) versus control; adjusted results (Continued)
2 1.054 0/13,980 8/15,087 0.06 (0.00 to
1.10)
3 1.054 0/13,980 7/15,087 0.07 (0.00 to
1.26)
Levine
1987i CHL
Cumulative
incidence
2.5 to 3
years
Enteric cap-
sules (3)
0.0015 25 1.036 33/20,847 16/5286 0.52 (0.29 to
0.95)
Levine
1987ii CHL
Cumulative
incidence
2.5 to 3
years
Enteric cap-
sules (3)
0.0015 25 1.036 22/21,400 16/5286 0.34 (0.18 to
0.65)
Levine
1990ii CHL
Cumulative
incidence
2.5 to 3
years
Enteric cap-
sules (3)
0.0015 15 1.021 62/33,982 14/4752 0.62 (0.35 to
1.11)
Wahdan
1980a EGY
Cumulative
incidence
2.5 to 3
years
Liquid for-
mulation (3)
0.0015 37b 1.054 0/13,980 21/15,087 0.03 (0.00 to
0.41)
Levine
1990i CHL
Cumulative
incidence
2.5 to 3
years
Liquid for-
mulation (3)
0.0015 15 1.021 23/35,870 14/5338 0.24 (0.13 to
0.47)
Levine
1987iii
CHL
Cumulative
incidence
2.5 to 3
years
Gelatin cap-
sules (3)
0.0015 25 1.036 44/20,792 16/5286 0.70 (0.39 to
1.24)
Levine
1987iv
CHL
Cumulative
incidence
2.5 to 3
years
Gelatin cap-
sules (3)
0.0015 26 1.0375 54/21,570 16/5279 0.83 (0.47 to
1.44)
Levine
1990i CHL
Cumulative
incidence
5 years
Liquid for-
mulation (3)
0.015 15 1.021 33/35,870 21/5338 0.23 (0.14 to
0.40)
Levine
1987ii CHL
Cumulative
incidence
7 years
Enteric cap-
sules (3)
0.015 25 1.036 48/21,400 32/5286 0.37 (0.24 to
0.58)
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Abbreviations: CI: confidence interval; ICC: intracluster correlation coefficient.
aICC calculated from Sur 2009 IND.
bAverage cluster size for Wahdan 1980a EGY calculated using pilot trial cluster size information.
Table 2. Cluster-randomized trials: efficacy of oral Ty21a vaccine: unadjusted resultsa
Trial Year Preparation (N doses) RR (95% CI)b Efficacyc
Black 1990ii CHL 1 Enteric capsules (1) 0.75 (0.48 to 1.18) 25% (−18% to 52%)
2 0.65 (0.36 to 1.18) 35% (−18% to 64%)
3 1.04 (0.47 to 2.31) −4% (−131% to 53%)
4 1.06 (0.56 to 2.00) −6% (−100% to 44%)
5 1.17 (0.51 to 2.68) −17% (−168% to 49%)
Cumulative 3 years 0.76 (0.55 to 1.06) 24% (−6% to 45%)
Cumulative 5 years 0.85 (0.65 to 1.12) 15% (−12% to 35%)
Black 1990i CHL 1 Enteric capsules (2) 0.48 (0.29 to 0.79) 52% (21% to 71%)
2 0.29 (0.14 to 0.60) 71% (40% to 86%)
3 0.74 (0.33 to 1.65) 26% (−65% to 67%)
4 0.81 (0.42 to 1.58) 19% (−58% to 58%)
5 0.88 (0.39 to 1.99) 12% (-99% to 61%)
Cumulative 3 years 0.46 (0.32 to 0.66) 54% (34% to 68%)
Cumulative 5 years 0.57 (0.42 to 0.76) 43% (24% to 58%)
Levine 1987ii CHL 1 Enteric capsules (3) 0.29 (0.10 to 0.86) 71% (14% to 90%)
2 0.40 (0.13 to 1.21) 60% (−21% to 87%)
3 0.33 (0.11 to 0.95) 67% (5% to 89%)
Wahdan 1980a EGY 1 Liquid formulation (3) 0.07 (0.00 to 1.26) 93% (−26% to 100%)
2 0.06 (0.00 to 1.10) 94% (−10% to 100%)
3 0.07 (0.00 to 1.26) 93% (−26% to 100%)
Levine 1987i CHL Cumulative incidence 2.
5 to 3 years
Enteric capsules (3) 0.51 (0.28 to 0.91) 49% (9% to 72%)
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Table 2. Cluster-randomized trials: efficacy of oral Ty21a vaccine: unadjusted resultsa (Continued)
Levine 1987ii CHL Cumulative incidence 2.
5 to 3 years
Enteric capsules (3) 0.33 (0.18 to 0.63) 67% (82% to 37%)
Levine 1990ii CHL Cumulative incidence 2.
5 to 3 years
Enteric capsules (3) 0.63 (0.35 to 1.12) 37% (−12% to 65%)
Wahdan 1980a EGY Cumulative incidence 2.
5 to 3 years
Liquid formulation (3) 0.02 (0.00 to 0.40) 98% (60% to 100%)
Levine 1990i CHL Cumulative incidence 2.
5 to 3 years
Liquid formulation (3) 0.24 (0.13 to 0.47) 76% (53% to 87%)
Levine 1987iii CHL Cumulative incidence 2.
5 to 3 years
Gelatin capsules (3) 0.69 (0.39 to 1.20) 31% (−20% to 61%)
Levine 1987iv CHL Cumulative incidence 2.
5 to 3 years
Gelatin capsules (3) 0.81 (0.47 to 1.39) 19% (−39% to 53%)
Levine 1990i CHL Cumulative incidence 5
years
Liquid preparation (3) 0.23 (0.13 to 0.39) 77% (61% to 87%)
Levine 1987ii CHL Cumulative incidence 7
years
Enteric capsules (3) 0.37 (0.24 to 0.58) 63% (42% to 76%)
Abbreviations: RR: risk ratio; CI: confidence interval.
aFailure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.
bRisk ratio with 95% CIs.
cEfficacy = 1 − risk ratio.
Table 3. Efficacy of Vi polysaccharide vaccine: unadjusted cluster-trial results by agea
Trial Year Age at baseline Typhoid episodes:Vi
vaccine
Typhoid episodes:
control
Efficacy (95% CI):
not adjusted
Khan 2012 PAK Cumulative
incidence at 2 years
2 to < 5 years 16/3154 13/3324 −30% (−183% to
40%)
5 to 16 years 14/10,084 36/10,669 59% (9% to 81%)
Sur 2009 IND Cumulative
incidence at 2 years
2 to < 5 years 5/1097 27/1095 82% (58% to 92%)
5 to < 15 years 21/4282 54/4584 59% (18% to 79%
≥ 15 years 8/13,490 15/13,125 48% (−44% to 81%)
aFailure to adjust for the potential effect of a cluster design is likely to lead to overestimation of the treatment effect.
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Table 4. Efficacy of Vi-TT (PedaTyph); cluster unadjusted results; year 1
Trial Number of
doses
Follow-up Vi-TT (PedaTyph) Control Risk ratio (96% CI) Efficacy (95% CI)
Events Total Events Total
Mitra 2016
IND
2 1 year 0 765 11 860 0.05 (0.00 to 0.83%) 95% (17% to 100%)
Abbreviations: CI: confidence interval.
WH A T ’ S N E W
Last assessed as up-to-date: 14 February 2018.
Date Event Description
3 May 2018 New citation required and conclusions have changed This review update includes one new trial, evaluating the
Vi-polysaccharide tetanus-toxoid conjugate vaccine (Vi-TT
PedaTyph)
6 March 2018 New search has been performed This is an update of Anwar 2014 with a new search up
to 14 February 2018. We have updated the Background
and adjusted the protocol to make clear that the review
does not include human challenge studies. We also updated
the protocol to exclude adverse effects comparison trials
using non-placebo vaccines as a control. We updated our
methods to include in themeta-analysis cluster-randomized
trials that we had previously described in separate tables
H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 4, 1998
Date Event Description
17 June 2013 New citation required but conclusions have not changed Four new trials added.
17 June 2013 New search has been performed This is an update of the review prepared by Fraser et al
(Fraser 2007a). This reviewupdate includes four new tri-
als, three evaluating the Vi polysaccharide vaccine (two
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(Continued)
reporting on efficacy and adverse events, one reporting
on adverse events only) and one evaluating the Vi-rEPA
vaccine (reporting adverse events)
22 August 2008 Amended Converted to new review format with minor editing.
26 April 2007 New citation required and conclusions have changed 2007, Issue 3: This review is an update of the original
version prepared by EA Engels and J Lau (Engels 1998a)
. This review evaluates the evidence available for a new
vaccine (Vi-rEPA) and includes 3 new efficacy trials that
were not included in Engels 1998a (1 evaluating the Vi-
rEPA and 2 evaluating the Vi polysaccharide vaccine)
. It would also have included head-on comparisons of
the different types of vaccines (not included in Engels
1998a) had these direct comparisons been conducted.
Since Engels 1998a was published, killed whole-cell vac-
cines are no longer in use and therefore are not included
in this review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this update, we excluded trials that reported on adverse events where typhoid vaccines were compared to an alternative vaccine rather
than placebo. This is because other vaccines may also have adverse events associated with them - such as fever or erythema at injection
site - and would not enable a true assessment of adverse events associated with typhoid vaccines. We excluded human challenge trials;
this had not been explicitly stated in the protocol but none were included in the previous review.
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use]
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